{
  "as_of": "2026-02-13",
  "items": [
    {
      "id": "milvexian",
      "name": "Milvexian",
      "type": "Drug",
      "category": "Stroke Prevention - FXI Inhibitors",
      "stage": "Phase 3",
      "mechanism": "Oral Factor XIa inhibitor",
      "focus": "Stroke prevention in AF and secondary stroke prevention",
      "company": "BMS / Johnson & Johnson",
      "latest_update": "ClinicalTrials.gov update posted 2026-02-13",
      "tags": [
        "FXI",
        "oral",
        "SPAF",
        "secondary stroke"
      ],
      "trials": [
        {
          "name": "LIBREXIA AF",
          "phase": "Phase 3",
          "status": "ACTIVE_NOT_RECRUITING",
          "readout": "Topline expected 2026",
          "readout_date": "2026-10-31",
          "registry_id": "NCT05757869",
          "note": "AF stroke prevention"
        },
        {
          "name": "LIBREXIA STROKE",
          "phase": "Phase 3",
          "status": "RECRUITING",
          "readout": "Topline expected 2026",
          "readout_date": "2026-11-11",
          "registry_id": "NCT05702034",
          "note": "Secondary stroke prevention"
        }
      ],
      "notes": "Librexia ACS was discontinued after interim analysis; AF and STROKE programs continue with 2026 readouts.",
      "sources": [
        "https://news.bms.com/news/details/2025/Update-on-Phase-3-Librexia-ACS-Trial/default.aspx"
      ]
    },
    {
      "id": "asundexian",
      "name": "Asundexian",
      "type": "Drug",
      "category": "Stroke Prevention - FXI Inhibitors",
      "stage": "Phase 3",
      "mechanism": "Oral Factor XIa inhibitor",
      "focus": "Secondary stroke prevention; AF program stopped",
      "company": "Bayer",
      "latest_update": "ClinicalTrials.gov update posted 2025-11-12",
      "press_2026": true,
      "tags": [
        "FXI",
        "oral",
        "secondary stroke"
      ],
      "trials": [
        {
          "name": "OCEANIC-AF",
          "phase": "Phase 3",
          "status": "Stopped early",
          "readout": "Stopped for lack of efficacy",
          "readout_date": "2023-11-15",
          "registry_id": null,
          "note": "AF stroke prevention vs apixaban"
        },
        {
          "name": "OCEANIC-STROKE",
          "phase": "Phase 3",
          "status": "COMPLETED",
          "readout": "ISC 2026 results (Feb 5, 2026)",
          "readout_date": "2025-10-23",
          "registry_id": "NCT05686070",
          "note": "Secondary stroke prevention"
        }
      ],
      "notes": "OCEANIC-STROKE reported a significant reduction in recurrent ischemic stroke with no increase in ISTH major bleeding vs placebo plus antiplatelet therapy.",
      "sources": [
        "https://www.bayer.com/media/en-us/oceanic-af-study-stopped-early-due-to-lack-of-efficacy/",
        "https://www.bayer.com/en/us/news-stories/asundexian-after-a-non-cardioembolic-ischemic-stroke",
        "https://www.bayer.com/media/en-us/bayers-asundexian-demonstrated-a-substantial-26-percent-reduction-in-stroke-after-a-non-cardioembolic-ischemic-stroke-or-high-risk-transient-ischemic-attack-with-no-increase-in-isth-major-bleeding-versus-placebo/"
      ]
    },
    {
      "id": "abelacimab",
      "name": "Abelacimab (MAA868)",
      "type": "Drug",
      "category": "Stroke Prevention - FXI Inhibitors",
      "stage": "Phase 3",
      "mechanism": "Monoclonal antibody targeting FXI/FXIa",
      "focus": "Stroke and systemic embolism prevention in AF",
      "company": "Novartis / Anthos Therapeutics",
      "latest_update": "Phase 3 development in AF; FDA Fast Track for AF stroke prevention",
      "tags": [
        "FXI",
        "mAb",
        "monthly"
      ],
      "trials": [
        {
          "name": "AZALEA-TIMI 71",
          "phase": "Phase 2",
          "status": "Completed",
          "readout": "Bleeding endpoint favored abelacimab vs rivaroxaban",
          "readout_date": null,
          "registry_id": null,
          "note": "AF moderate-to-high risk"
        },
        {
          "name": "Phase 3 AF program",
          "phase": "Phase 3",
          "status": "Ongoing",
          "readout": "TBD",
          "readout_date": null,
          "registry_id": null,
          "note": "Stroke and systemic embolism prevention"
        }
      ],
      "notes": "Novartis announced abelacimab as a late-stage AF asset with Phase 3 development for stroke/systemic embolism prevention; Anthos reports Phase 2 AZALEA-TIMI 71 and Phase 3 enrollment milestones.",
      "sources": [
        "https://www.novartis.com/news/media-releases/novartis-bolsters-late-stage-cardiovascular-pipeline-agreement-acquire-anthos-therapeutics-usd-925-million-upfront",
        "https://anthostherapeutics.com/press-release/anthos_2024-08-15_release-10/",
        "https://anthostherapeutics.com/press-release/anthos_2024-08-27_release/"
      ]
    },
    {
      "id": "shr-2004",
      "name": "SHR-2004",
      "type": "Drug",
      "category": "Stroke Prevention - FXI Inhibitors",
      "stage": "Phase 1b",
      "mechanism": "Humanized monoclonal antibody targeting Factor XI",
      "focus": "Anticoagulation in AF with reduced bleeding risk",
      "company": "Jiangsu Hengrui",
      "latest_update": "ClinicalTrials.gov update posted 2024-02-28",
      "tags": [
        "FXI",
        "mAb",
        "AF"
      ],
      "trials": [
        {
          "name": "SHR-2004-102",
          "phase": "Phase 1b",
          "status": "NOT_YET_RECRUITING",
          "readout": "EHJ 2025 abstract",
          "readout_date": "2024-12-31",
          "registry_id": "NCT06280768",
          "note": "Multiple SC injections in AF"
        }
      ],
      "notes": "Phase 1b AF study evaluated safety, tolerability, PK/PD; presented at ESC 2025 (EHJ supplement).",
      "sources": [
        "https://clinicaltrials.gov/study/NCT06280768",
        "https://academic.oup.com/eurheartj/article/46/Supplement_1/ehaf784.4260/8310619"
      ]
    },
    {
      "id": "regn7508",
      "name": "REGN7508",
      "type": "Drug",
      "category": "Stroke Prevention - FXI Inhibitors",
      "stage": "Phase 2 (AF); Phase 3 in VTE",
      "mechanism": "Monoclonal antibody targeting FXI catalytic domain",
      "focus": "Anticoagulation with reduced bleeding risk; AF stroke prevention program planned",
      "company": "Regeneron",
      "latest_update": "ClinicalTrials.gov update posted 2026-02-05",
      "tags": [
        "FXI",
        "mAb",
        "AF",
        "stroke prevention"
      ],
      "trials": [
        {
          "name": "ROXI-ATLAS",
          "phase": "Phase 2",
          "status": "RECRUITING",
          "readout": "Completion expected 2027",
          "readout_date": "2027-02-09",
          "registry_id": "NCT07175428",
          "note": "AF safety vs apixaban"
        },
        {
          "name": "ROXI-VTE-II",
          "phase": "Phase 2",
          "status": "Published",
          "readout": "Lancet 2025",
          "readout_date": "2025-11-08",
          "registry_id": "NCT06454630",
          "note": "Post\u2011TKA VTE prevention"
        }
      ],
      "notes": "Factor XI catalytic\u2011domain antibody; Phase 2 VTE proof\u2011of\u2011concept published; AF safety trial ongoing and Phase 3 AF program planned.",
      "sources": [
        "https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-advance-two-factor-xi-antibodies-broad-phase-3-program",
        "https://fdaaa.trialstracker.net/trial/NCT07175428/",
        "https://pubmed.ncbi.nlm.nih.gov/41218619/",
        "https://www.globenewswire.com/news-release/2025/11/08/3184069/0/en/Phase-2-Trials-Demonstrating-Antithrombotic-Effect-of-Two-Novel-Regeneron-Factor-XI-Antibodies-Presented-at-American-Heart-Association-Scientific-Sessions-and-Published-in-The-Lanc.html"
      ]
    },
    {
      "id": "regn9933",
      "name": "REGN9933",
      "type": "Drug",
      "category": "Stroke Prevention - FXI Inhibitors",
      "stage": "Phase 2 (AF); Phase 2 completed in VTE",
      "mechanism": "Monoclonal antibody targeting FXI A2 domain",
      "focus": "Anticoagulation for patients with higher bleeding risk; AF safety program",
      "company": "Regeneron",
      "latest_update": "ClinicalTrials.gov update posted 2026-02-05",
      "tags": [
        "FXI",
        "mAb",
        "AF",
        "bleeding risk"
      ],
      "trials": [
        {
          "name": "ROXI-ATLAS",
          "phase": "Phase 2",
          "status": "RECRUITING",
          "readout": "Completion expected 2027",
          "readout_date": "2027-02-09",
          "registry_id": "NCT07175428",
          "note": "AF safety vs apixaban"
        },
        {
          "name": "ROXI-VTE-I",
          "phase": "Phase 2",
          "status": "Published",
          "readout": "Lancet 2025",
          "readout_date": "2025-11-08",
          "registry_id": "NCT05618808",
          "note": "Post\u2011TKA VTE prevention"
        }
      ],
      "notes": "FXI A2\u2011domain antibody; Phase 2 VTE proof\u2011of\u2011concept published; AF safety trial ongoing alongside REGN7508.",
      "sources": [
        "https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-advance-two-factor-xi-antibodies-broad-phase-3-program",
        "https://fdaaa.trialstracker.net/trial/NCT07175428/",
        "https://pubmed.ncbi.nlm.nih.gov/41218619/",
        "https://www.globenewswire.com/news-release/2025/11/08/3184069/0/en/Phase-2-Trials-Demonstrating-Antithrombotic-Effect-of-Two-Novel-Regeneron-Factor-XI-Antibodies-Presented-at-American-Heart-Association-Scientific-Sessions-and-Published-in-The-Lanc.html"
      ]
    },
    {
      "id": "srsd107",
      "name": "SRSD107",
      "type": "Drug",
      "category": "Stroke Prevention - FXI Inhibitors",
      "stage": "Phase 2",
      "mechanism": "Long-acting FXI siRNA",
      "focus": "Thromboembolic disorders including AF stroke prevention",
      "company": "Sirius Therapeutics / CRISPR Therapeutics",
      "latest_update": "EMA authorization to initiate Phase 2 in July 2025",
      "tags": [
        "FXI",
        "siRNA",
        "long-acting"
      ],
      "trials": [
        {
          "name": "SRSD107 Phase 2",
          "phase": "Phase 2",
          "status": "Authorized",
          "readout": "TBD",
          "readout_date": null,
          "registry_id": null,
          "note": "EU multi-country"
        }
      ],
      "notes": "Next-generation FXI siRNA program with Phase 2 EU authorization; intended for thromboembolic disorders.",
      "sources": [
        "https://www.siriusrna.com/html/companynews/81.html"
      ]
    },
    {
      "id": "apixaban",
      "name": "Apixaban (Eliquis)",
      "type": "Drug",
      "category": "Stroke Prevention - Anticoagulants",
      "stage": "Approved",
      "mechanism": "Direct oral anticoagulant (Factor Xa inhibitor)",
      "focus": "Stroke prevention in AF",
      "company": "BMS / Pfizer",
      "latest_update": "DOACs preferred over warfarin in most AF patients",
      "tags": [
        "DOAC",
        "Factor Xa"
      ],
      "trials": [
        {
          "name": "Guideline recommendation",
          "phase": "Guideline",
          "status": "Preferred",
          "readout": "2023 ACC/AHA/ACCP/HRS guideline",
          "readout_date": "2023-11-30",
          "registry_id": null,
          "note": "Preferred over warfarin except mitral stenosis or mechanical valve"
        }
      ],
      "notes": "Standard-of-care anticoagulant for non-valvular AF.",
      "sources": [
        "https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2023/11/27/19/46/2023-acc-guideline-for-af-gl-af"
      ]
    },
    {
      "id": "bay-3670549",
      "name": "BAY 3670549",
      "type": "Drug",
      "category": "Rhythm Control - Antiarrhythmic Drugs",
      "stage": "Phase 1",
      "mechanism": "Selective GIRK4 inhibitor",
      "focus": "Rapid pharmacologic cardioversion in AF",
      "company": "Bayer",
      "latest_update": "Phase 1 first\u2011in\u2011human study initiated (May 2025)",
      "tags": [
        "GIRK4",
        "cardioversion",
        "acute"
      ],
      "trials": [
        {
          "name": "BAY 3670549 Phase 1",
          "phase": "Phase 1",
          "status": "Initiated",
          "readout": "TBD",
          "readout_date": null,
          "registry_id": null,
          "note": "Healthy participants dose escalation"
        }
      ],
      "notes": "Investigational GIRK4 inhibitor aimed at rapid cardioversion without anesthesia or electrical shock.",
      "sources": [
        "https://www.bayer.com/media/en-us/bayer-starts-phase-i-study-with-girk4-inhibitor-for-treatment-of-patients-with-atrial-fibrillation/",
        "https://www.bayer.com/en/us/news-stories/rapid-cardioversion"
      ]
    },
    {
      "id": "rivaroxaban",
      "name": "Rivaroxaban (Xarelto)",
      "type": "Drug",
      "category": "Stroke Prevention - Anticoagulants",
      "stage": "Approved",
      "mechanism": "Direct oral anticoagulant (Factor Xa inhibitor)",
      "focus": "Stroke prevention in AF",
      "company": "Bayer / Janssen",
      "latest_update": "DOACs preferred over warfarin in most AF patients",
      "tags": [
        "DOAC",
        "Factor Xa"
      ],
      "trials": [
        {
          "name": "Guideline recommendation",
          "phase": "Guideline",
          "status": "Preferred",
          "readout": "2023 ACC/AHA/ACCP/HRS guideline",
          "readout_date": "2023-11-30",
          "registry_id": null,
          "note": "Preferred over warfarin except mitral stenosis or mechanical valve"
        }
      ],
      "notes": "Standard-of-care anticoagulant for non-valvular AF.",
      "sources": [
        "https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2023/11/27/19/46/2023-acc-guideline-for-af-gl-af"
      ]
    },
    {
      "id": "dabigatran",
      "name": "Dabigatran (Pradaxa)",
      "type": "Drug",
      "category": "Stroke Prevention - Anticoagulants",
      "stage": "Approved",
      "mechanism": "Direct oral anticoagulant (direct thrombin inhibitor)",
      "focus": "Stroke prevention in AF",
      "company": "Boehringer Ingelheim",
      "latest_update": "DOACs preferred over warfarin in most AF patients",
      "tags": [
        "DOAC",
        "thrombin"
      ],
      "trials": [
        {
          "name": "Guideline recommendation",
          "phase": "Guideline",
          "status": "Preferred",
          "readout": "2023 ACC/AHA/ACCP/HRS guideline",
          "readout_date": "2023-11-30",
          "registry_id": null,
          "note": "Preferred over warfarin except mitral stenosis or mechanical valve"
        }
      ],
      "notes": "Standard-of-care anticoagulant for non-valvular AF.",
      "sources": [
        "https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2023/11/27/19/46/2023-acc-guideline-for-af-gl-af"
      ]
    },
    {
      "id": "edoxaban",
      "name": "Edoxaban (Savaysa)",
      "type": "Drug",
      "category": "Stroke Prevention - Anticoagulants",
      "stage": "Approved",
      "mechanism": "Direct oral anticoagulant (Factor Xa inhibitor)",
      "focus": "Stroke prevention in AF",
      "company": "Daiichi Sankyo",
      "latest_update": "DOACs preferred over warfarin in most AF patients",
      "tags": [
        "DOAC",
        "Factor Xa"
      ],
      "trials": [
        {
          "name": "Guideline recommendation",
          "phase": "Guideline",
          "status": "Preferred",
          "readout": "2023 ACC/AHA/ACCP/HRS guideline",
          "readout_date": "2023-11-30",
          "registry_id": null,
          "note": "Preferred over warfarin except mitral stenosis or mechanical valve"
        }
      ],
      "notes": "Standard-of-care anticoagulant for non-valvular AF.",
      "sources": [
        "https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2023/11/27/19/46/2023-acc-guideline-for-af-gl-af"
      ]
    },
    {
      "id": "warfarin",
      "name": "Warfarin",
      "type": "Drug",
      "category": "Stroke Prevention - Anticoagulants",
      "stage": "Approved",
      "mechanism": "Vitamin K antagonist",
      "focus": "Stroke prevention in AF",
      "company": "Generic",
      "latest_update": "Preferred in AF with moderate-severe mitral stenosis or mechanical valves",
      "tags": [
        "VKA"
      ],
      "trials": [
        {
          "name": "Guideline recommendation",
          "phase": "Guideline",
          "status": "Indicated in specific populations",
          "readout": "2023 ACC/AHA/ACCP/HRS guideline",
          "readout_date": "2023-11-30",
          "registry_id": null,
          "note": "Used when DOACs are not appropriate"
        }
      ],
      "notes": "Standard anticoagulant for valvular AF or mechanical valves.",
      "sources": [
        "https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2023/11/27/19/46/2023-acc-guideline-for-af-gl-af"
      ]
    },
    {
      "id": "tecarfarin",
      "name": "Tecarfarin",
      "type": "Drug",
      "category": "Stroke Prevention - Anticoagulants",
      "stage": "Late-stage (ESKD + AF planned trial)",
      "mechanism": "Vitamin K antagonist (VKA)",
      "focus": "Anticoagulation in ESKD + AF; stroke/systemic thromboembolism prevention",
      "company": "Cadrenal Therapeutics",
      "latest_update": "Clinical trial initiation plans announced for ESKD patients transitioning to dialysis; FDA Fast Track and ODD for ESKD+AF",
      "tags": [
        "VKA",
        "ESKD",
        "AF"
      ],
      "trials": [
        {
          "name": "ESKD transitioning to dialysis trial",
          "phase": "Late-stage",
          "status": "Planned",
          "readout": "TBD",
          "readout_date": null,
          "registry_id": null,
          "note": "Includes patients with and without AF"
        }
      ],
      "notes": "Cadrenal plans an ESKD trial (including AF) and holds FDA Fast Track and orphan designations for ESKD+AF.",
      "sources": [
        "https://www.businesswire.com/news/home/20250805824561/en/Cadrenal-Therapeutics-Announces-Clinical-Trial-Initiation-Plans-for-Tecarfarin-in-Patients-with-End-Stage-Kidney-Disease-ESKD-Transitioning-to-Dialysis",
        "https://www.prnewswire.com/news-releases/cadrenal-therapeutics-nasdaq-cvkd-granted-fda-fast-track-designation-for-tecarfarin-for-prevention-of-systemic-thromboembolism-of-cardiac-origin-in-patients-with-end-stage-renal-disease-and-atrial-fibrillation-301727778.html",
        "https://www.businesswire.com/news/home/20250811315782/en/Cadrenal-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Update"
      ]
    },
    {
      "id": "adx-626",
      "name": "ADX-626",
      "type": "Drug",
      "category": "Stroke Prevention - FXI Inhibitors",
      "stage": "Phase 1",
      "mechanism": "siRNA targeting Factor XI",
      "focus": "Thrombotic diseases including AF stroke prevention",
      "company": "ADARx Pharmaceuticals",
      "latest_update": "Phase 1 ongoing; AF listed as target indication on pipeline",
      "tags": [
        "FXI",
        "siRNA",
        "long-acting"
      ],
      "trials": [],
      "notes": "ADX-626 is an siRNA program targeting Factor XI with AF, stroke, and thrombotic diseases listed among intended indications.",
      "sources": [
        "https://www.adarx.com/pipeline/"
      ]
    },
    {
      "id": "procase-ab002",
      "name": "proCase (AB002)",
      "type": "Drug",
      "category": "Stroke Prevention - Novel Antithrombotics",
      "stage": "Phase 2",
      "mechanism": "Thrombin analog (protein C pathway activator)",
      "focus": "Acute cardiovascular thrombosis; potential anticoagulation applications",
      "company": "Aronora (royalties held by XOMA)",
      "latest_update": "Aronora lists AB002 as Phase 2 with FDA Fast Track designation",
      "tags": [
        "thrombin analog",
        "protein C",
        "antithrombotic"
      ],
      "trials": [],
      "notes": "Aronora pipeline lists AB002 (proCase) in Phase 2 with FDA Fast Track; XOMA reports royalty interest.",
      "sources": [
        "https://aronorabio.com/pipeline/",
        "https://investors.xoma.com/news-events/press-releases/detail/350/xoma-acquires-royalty-rights-to-five-hematology-candidates"
      ]
    },
    {
      "id": "compound-006",
      "name": "Compound-006",
      "type": "Drug",
      "category": "Stroke Prevention - Novel Antithrombotics",
      "stage": "Preclinical",
      "mechanism": "NMMHC IIA inhibitor",
      "focus": "Arterial thrombosis (preclinical)",
      "company": "Protheragen",
      "latest_update": "Preclinical efficacy reported in arterial thrombosis models",
      "tags": [
        "NMMHC IIA",
        "preclinical"
      ],
      "trials": [],
      "notes": "Protheragen reports preclinical efficacy of NMMHC IIA inhibitors in thrombosis models.",
      "sources": [
        "https://www.protheragen.com/available-projects/small-molecule-nmmhc-iia-inhibitors/"
      ]
    },
    {
      "id": "compound-011",
      "name": "Compound-011",
      "type": "Drug",
      "category": "Stroke Prevention - Novel Antithrombotics",
      "stage": "Preclinical",
      "mechanism": "NMMHC IIA inhibitor",
      "focus": "Venous thrombosis (preclinical)",
      "company": "Protheragen",
      "latest_update": "Preclinical efficacy reported in DVT models",
      "tags": [
        "NMMHC IIA",
        "preclinical"
      ],
      "trials": [],
      "notes": "Protheragen reports preclinical efficacy of NMMHC IIA inhibitors in thrombosis models.",
      "sources": [
        "https://www.protheragen.com/available-projects/small-molecule-nmmhc-iia-inhibitors/"
      ]
    },
    {
      "id": "pkn605",
      "name": "PKN605 (aka CKD-510)",
      "type": "Drug",
      "category": "Disease Modification - AF Remodeling",
      "stage": "Phase 2",
      "mechanism": "Oral investigational therapy (mechanism not disclosed publicly)",
      "focus": "Reduction of AF burden; HDAC6 inhibitor licensed from Chong Kun Dang",
      "company": "Novartis (licensed from Chong Kun Dang)",
      "latest_update": "ClinicalTrials.gov update posted 2026-01-26",
      "tags": [
        "AF burden",
        "Phase 2",
        "HDAC6"
      ],
      "trials": [
        {
          "name": "CPKN605A12201",
          "phase": "Phase 2",
          "status": "RECRUITING",
          "readout": "TBD",
          "readout_date": "2027-09-09",
          "registry_id": "NCT07217067",
          "note": "AF burden reduction"
        }
      ],
      "notes": "Novartis study evaluating efficacy, safety, tolerability, and PK in participants with AF; CKD-510 reported as the same licensed HDAC6 inhibitor.",
      "sources": [
        "https://www.novartis.com/clinicaltrials/study/nct07217067",
        "https://www.koreabiomed.com/news/articleView.html?idxno=27651"
      ]
    },
    {
      "id": "ve-1902",
      "name": "VE-1902",
      "type": "Drug",
      "category": "Stroke Prevention - Anticoagulants",
      "stage": "Phase 1",
      "mechanism": "Precision oral anticoagulant (direct thrombin inhibitor)",
      "focus": "Stroke and heart attack prevention with reduced bleeding risk",
      "company": "Verseon",
      "latest_update": "Phase 1; preclinical efficacy published",
      "tags": [
        "PROAC",
        "thrombin",
        "oral"
      ],
      "trials": [],
      "notes": "Verseon PROAC candidate in Phase 1; preclinical thrombin inhibitor data published.",
      "sources": [
        "https://www.verseon.com/pipeline-1-anticoagulation.html",
        "https://www.verseon.com/news-efficacyanticoagulant_content.html"
      ]
    },
    {
      "id": "ve-2851",
      "name": "VE-2851",
      "type": "Drug",
      "category": "Stroke Prevention - Anticoagulants",
      "stage": "Preclinical",
      "mechanism": "Precision oral anticoagulant (direct thrombin inhibitor)",
      "focus": "Stroke and heart attack prevention with reduced bleeding risk",
      "company": "Verseon",
      "latest_update": "Preclinical; second-generation PROAC candidate",
      "tags": [
        "PROAC",
        "thrombin",
        "oral"
      ],
      "trials": [],
      "notes": "Second-generation PROAC candidate listed as preclinical on Verseon pipeline.",
      "sources": [
        "https://www.verseon.com/pipeline-1-anticoagulation.html",
        "https://www.verseon.com/pipeline.html"
      ]
    },
    {
      "id": "tah3311",
      "name": "TAH3311 (Apixaban ODF)",
      "type": "Drug",
      "category": "Stroke Prevention - Anticoagulants",
      "stage": "NDA submitted",
      "mechanism": "Apixaban oral dissolving film (ODF) formulation",
      "focus": "Stroke prevention and thromboembolic disorders (apixaban reformulation)",
      "company": "TAHO Pharmaceuticals",
      "latest_update": "Pivotal bioequivalence study completed; NDA submitted Oct 2025",
      "tags": [
        "apixaban",
        "ODF",
        "formulation"
      ],
      "trials": [
        {
          "name": "Pivotal bioequivalence study",
          "phase": "Phase 3",
          "status": "Completed",
          "readout": "Bioequivalent to Eliquis under fasting conditions",
          "readout_date": "2025-05-08",
          "registry_id": null,
          "note": "505(b)(2) bioequivalence pathway"
        }
      ],
      "notes": "Oral dissolving film reformulation of apixaban designed for patients with swallowing difficulties; NDA submitted in 2025.",
      "sources": [
        "https://www.tahopharma.com/en/news-detail/88/",
        "https://www.tahopharma.com/en/news-detail/102/",
        "https://www.prnewswire.com/news-releases/taho-pharma-announces-submission-of-new-drug-application-nda-to-the-us-fda-for-tah3311--the-worlds-first-apixaban-oral-dissolving-film--represents-a-transformational-advancement-in-anticoagulant-therapy-302572050.html"
      ]
    },
    {
      "id": "tah3341",
      "name": "TAH3341 (Apixaban ER Film)",
      "type": "Drug",
      "category": "Stroke Prevention - Anticoagulants",
      "stage": "Pipeline",
      "mechanism": "Apixaban oral extended-release film",
      "focus": "Anticoagulation (apixaban reformulation)",
      "company": "TAHO Pharmaceuticals",
      "latest_update": "Listed in company pipeline as apixaban oral extended\u2011release film",
      "tags": [
        "apixaban",
        "ER",
        "formulation"
      ],
      "trials": [],
      "notes": "Pipeline reformulation of apixaban in extended\u2011release oral film format.",
      "sources": [
        "https://www.tahopharma.com/en/product/",
        "https://www.biodriven.taipei/en/GetDownloadFile.aspx/9b27598f-9c06-4fb3-8444-82ab6d8ba40a"
      ]
    },
    {
      "id": "kv998083",
      "name": "KV998083",
      "type": "Drug",
      "category": "Stroke Prevention - FXII Inhibitors",
      "stage": "Preclinical",
      "mechanism": "Oral FXIIa inhibitor",
      "focus": "Antithrombotic therapy with reduced bleeding risk",
      "company": "KalVista Pharmaceuticals",
      "latest_update": "Preclinical FXIIa inhibitor described in KalVista scientific presentation",
      "tags": [
        "FXII",
        "oral",
        "preclinical"
      ],
      "trials": [],
      "notes": "Preclinical small\u2011molecule FXIIa inhibitor; development status beyond early research not publicly detailed.",
      "sources": [
        "https://www.kalvista.com/sites/default/files/Kinin2022_NIM_Zymogen_06-01_PRINT.pdf"
      ]
    },
    {
      "id": "mpi-8",
      "name": "MPI-8 (Macromolecular Polyphosphate Inhibitor 8)",
      "type": "Drug",
      "category": "Stroke Prevention - Novel Antithrombotics",
      "stage": "Preclinical",
      "mechanism": "Polyphosphate inhibitor (targets platelet polyP)",
      "focus": "Antithrombotic therapy with reduced bleeding risk",
      "company": "Academic (University of Michigan / UBC)",
      "latest_update": "Preclinical reports show antithrombotic activity with reduced bleeding risk",
      "tags": [
        "polyphosphate",
        "preclinical"
      ],
      "trials": [],
      "notes": "Academic preclinical candidate; not yet in clinical trials.",
      "sources": [
        "https://www.mdpi.com/2218-273X/15/10/1441",
        "https://twojezdrowie.rmf24.pl/aktualnosci/news-sa-szanse-na-przeciwzakrzepowa-rewolucje%2CnId%2C6741188"
      ]
    },
    {
      "id": "amiodarone",
      "name": "Amiodarone",
      "type": "Drug",
      "category": "Rhythm Control - Antiarrhythmic Drugs",
      "stage": "Approved",
      "mechanism": "Class III antiarrhythmic (multi-channel blocker)",
      "focus": "Rhythm control in AF",
      "company": "Generic",
      "latest_update": "Standard antiarrhythmic option for rhythm control",
      "tags": [
        "AAD",
        "Class III"
      ],
      "trials": [],
      "notes": "Widely used rhythm control drug; requires monitoring for toxicities.",
      "sources": []
    },
    {
      "id": "dronedarone",
      "name": "Dronedarone (Multaq)",
      "type": "Drug",
      "category": "Rhythm Control - Antiarrhythmic Drugs",
      "stage": "Approved",
      "mechanism": "Class III antiarrhythmic",
      "focus": "Rhythm control in AF",
      "company": "Sanofi",
      "latest_update": "Standard antiarrhythmic option for rhythm control",
      "tags": [
        "AAD",
        "Class III"
      ],
      "trials": [],
      "notes": "Rhythm control option for selected patients.",
      "sources": []
    },
    {
      "id": "ap31969",
      "name": "AP31969",
      "type": "Drug",
      "category": "Rhythm Control - Antiarrhythmic Drugs",
      "stage": "Phase 2",
      "mechanism": "Oral SK ion channel inhibitor",
      "focus": "Rhythm control in AF; reduction in AF burden",
      "company": "Acesion Pharma",
      "latest_update": "ClinicalTrials.gov update posted 2025-12-05",
      "tags": [
        "SK channel",
        "AAD",
        "first-in-class"
      ],
      "trials": [
        {
          "name": "AP31969 Phase 2",
          "phase": "Phase 2",
          "status": "RECRUITING",
          "readout": "Completion expected Q1 2027",
          "readout_date": "2026-11",
          "registry_id": "NCT07267949",
          "note": "AF burden endpoint"
        }
      ],
      "notes": "First-in-class SK ion channel inhibitor; randomized, double-blind, placebo-controlled dose-finding Phase 2 in AF patients.",
      "sources": [
        "https://www.prnewswire.com/news-releases/acesion-pharma-starts-phase-2-trial-of-ap31969-in-patients-with-atrial-fibrillation-302652837.html",
        "https://www.pharmiweb.com/press-release/2026-01-06/acesion-pharma-starts-phase-2-trial-of-ap31969-in-patients-with-atrial-fibrillation"
      ]
    },
    {
      "id": "dofetilide",
      "name": "Dofetilide",
      "type": "Drug",
      "category": "Rhythm Control - Antiarrhythmic Drugs",
      "stage": "Approved",
      "mechanism": "Class III antiarrhythmic",
      "focus": "Rhythm control in AF",
      "company": "Generic",
      "latest_update": "Standard antiarrhythmic option for rhythm control",
      "tags": [
        "AAD",
        "Class III"
      ],
      "trials": [],
      "notes": "Initiation requires monitoring due to QT prolongation risk.",
      "sources": []
    },
    {
      "id": "sotalol",
      "name": "Sotalol",
      "type": "Drug",
      "category": "Rhythm Control - Antiarrhythmic Drugs",
      "stage": "Approved",
      "mechanism": "Class III antiarrhythmic with beta-blocking",
      "focus": "Rhythm control in AF",
      "company": "Generic",
      "latest_update": "Standard antiarrhythmic option for rhythm control",
      "tags": [
        "AAD",
        "Class III",
        "beta blocker"
      ],
      "trials": [],
      "notes": "Requires monitoring for QT prolongation and renal dosing.",
      "sources": []
    },
    {
      "id": "flecainide",
      "name": "Flecainide",
      "type": "Drug",
      "category": "Rhythm Control - Antiarrhythmic Drugs",
      "stage": "Approved",
      "mechanism": "Class Ic antiarrhythmic",
      "focus": "Rhythm control in AF",
      "company": "Generic",
      "latest_update": "Standard antiarrhythmic option for rhythm control",
      "tags": [
        "AAD",
        "Class Ic"
      ],
      "trials": [],
      "notes": "Used in structurally normal hearts; avoid in structural heart disease.",
      "sources": []
    },
    {
      "id": "propafenone",
      "name": "Propafenone",
      "type": "Drug",
      "category": "Rhythm Control - Antiarrhythmic Drugs",
      "stage": "Approved",
      "mechanism": "Class Ic antiarrhythmic",
      "focus": "Rhythm control in AF",
      "company": "Generic",
      "latest_update": "Standard antiarrhythmic option for rhythm control",
      "tags": [
        "AAD",
        "Class Ic"
      ],
      "trials": [],
      "notes": "Used in selected patients; avoid in structural heart disease.",
      "sources": []
    },
    {
      "id": "etripamil",
      "name": "Etripamil (Cardamyst)",
      "type": "Drug",
      "category": "Rate Control - Acute AFib-RVR",
      "stage": "Phase 3",
      "mechanism": "Intranasal calcium channel blocker (short-acting)",
      "focus": "Acute treatment of AFib with rapid ventricular rate (AFib-RVR)",
      "company": "Milestone Pharmaceuticals",
      "latest_update": "Company states Phase 3 development for AFib-RVR in adults",
      "tags": [
        "intranasal",
        "AFib-RVR",
        "acute care"
      ],
      "trials": [
        {
          "name": "ReVeRA",
          "phase": "Phase 2",
          "status": "Completed",
          "readout": "Positive Phase 2 results presented at AHA 2023",
          "readout_date": "2023-11-11",
          "registry_id": null,
          "note": "AFib-RVR rate reduction"
        },
        {
          "name": "AFib-RVR Phase 3 program",
          "phase": "Phase 3",
          "status": "Planned",
          "readout": "TBD",
          "readout_date": null,
          "registry_id": null,
          "note": "Self-administered nasal spray"
        }
      ],
      "notes": "Intranasal, rapid-acting calcium channel blocker being developed for episodic AFib-RVR; Phase 2 ReVeRA supported Phase 3 planning.",
      "sources": [
        "https://milestonepharma.com/pipeline/etripamil/",
        "https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-presents-positive-results-from-revera-phase-2-study-of-etripamil-in-afib-rvr-at-the-american-heart-association-scientific-sessions-2023-301985199.html"
      ]
    },
    {
      "id": "inrhythm-flecainide",
      "name": "InRhythm (inhaled flecainide)",
      "type": "Drug",
      "category": "Rhythm Control - Antiarrhythmic Drugs",
      "stage": "Phase 2",
      "mechanism": "Inhaled delivery of flecainide",
      "focus": "Rapid cardioversion of recent-onset paroxysmal AF",
      "company": "InCarda Therapeutics",
      "latest_update": "Phase 2 INSTANT results; optimal dose identified; company plans Phase 3",
      "tags": [
        "flecainide",
        "inhaled",
        "pill-in-the-pocket"
      ],
      "trials": [
        {
          "name": "INSTANT",
          "phase": "Phase 2",
          "status": "Completed",
          "readout": "Phase 2 results presented at AHA 2022; publication in 2022",
          "readout_date": "2022-11-07",
          "registry_id": null,
          "note": "Recent-onset paroxysmal AF"
        }
      ],
      "notes": "Orally inhaled flecainide aims to provide rapid conversion to sinus rhythm; Phase 2 dose-finding identified 120 mg for Phase 3 planning.",
      "sources": [
        "https://incardatherapeutics.com/2022/11/07/final-results-from-phase-2-instant-trial-of-inrhythm-for-the-treatment-of-newly-diagnosed-and-recurrent-paroxysmal-atrial-fibrillation-presented-at-2022-american-heart-association-scientific/",
        "https://incardatherapeutics.com/2022/04/06/incarda-therapeutics-announces-publication-of-phase-2-data-demonstrating-inhaled-flecainide-for-conversion-of-atrial-fibrillation-to-sinus-rhythm-is-safe-and-effective/"
      ]
    },
    {
      "id": "thrv-1268",
      "name": "THRV-1268",
      "type": "Drug",
      "category": "Disease Modification - AF Remodeling",
      "stage": "Phase 1",
      "mechanism": "SGK1 inhibitor",
      "focus": "AF remodeling and cardiometabolic disease",
      "company": "Thryv Therapeutics",
      "latest_update": "ClinicalTrials.gov update posted 2025-05-13",
      "tags": [
        "SGK1",
        "remodeling",
        "preclinical AF"
      ],
      "trials": [
        {
          "name": "THRV-1268 Phase 1",
          "phase": "Phase 1",
          "status": "COMPLETED",
          "readout": "Phase 1 completed; IND clearance for AF program",
          "readout_date": "2024-11-01",
          "registry_id": "NCT06507839",
          "note": "Healthy volunteers"
        },
        {
          "name": "Phase 2 AF program",
          "phase": "Phase 2",
          "status": "Planned",
          "readout": "Planned to begin in 2026",
          "readout_date": null,
          "registry_id": null,
          "note": "Proof-of-efficacy in AF"
        }
      ],
      "notes": "SGK1 inhibitor with preclinical AF signal and completed Phase 1; company plans AF proof-of-efficacy study in 2026.",
      "sources": [
        "https://thryvtrx.com/news/phase-1-dosing-thrv1268",
        "https://thryvtrx.com/news/1268-ind-esc-2025-results"
      ]
    },
    {
      "id": "lqt-1213",
      "name": "LQT-1213 (Islasertib)",
      "type": "Drug",
      "category": "Rhythm Control - Antiarrhythmic Drugs",
      "stage": "Preclinical",
      "mechanism": "Oral small-molecule antiarrhythmic (mechanism not publicly detailed)",
      "focus": "Long QT syndrome and arrhythmia risk; potential AF relevance under evaluation",
      "company": "Thryv Therapeutics",
      "latest_update": "Wave I proof\u2011of\u2011concept completed for LQT\u20111213 (Islasertib)",
      "tags": [
        "preclinical",
        "arrhythmia",
        "LQT"
      ],
      "trials": [],
      "notes": "Thryv reports proof\u2011of\u2011concept for LQT\u20111213 (Islasertib); AF indication not yet specified.",
      "sources": [
        "https://thryvtrx.com/news/wavei-proof-of-concept-lqt1213"
      ]
    },
    {
      "id": "at-6616",
      "name": "AT6616",
      "type": "Drug",
      "category": "Disease Modification - AF Remodeling",
      "stage": "Preclinical",
      "mechanism": "Undisclosed",
      "focus": "Atrial fibrillation",
      "company": "Abelian Pharmaceutical (pipeline in HKEX listing draft)",
      "latest_update": "Listed as preclinical AFib program in 2025 HKEX listing draft",
      "tags": [
        "preclinical",
        "AF"
      ],
      "trials": [],
      "notes": "Program listed as an undisclosed AFib asset in preclinical stage.",
      "sources": [
        "https://www1.hkexnews.hk/app/sehk/2025/107685/a125609/sehk25091501547.pdf"
      ]
    },
    {
      "id": "ctp-amio",
      "name": "CTP\u2011Amio",
      "type": "Drug",
      "category": "Rhythm Control - Antiarrhythmic Drugs",
      "stage": "Preclinical / grant-funded",
      "mechanism": "Cardiac targeting peptide conjugated to amiodarone",
      "focus": "AF treatment with reduced systemic toxicity",
      "company": "Vivasc Therapeutics / University of Pittsburgh",
      "latest_update": "NIH PHI STTR award reported for CTP\u2011Amio development (2022)",
      "tags": [
        "amiodarone",
        "targeted delivery",
        "preclinical"
      ],
      "trials": [],
      "notes": "CTP\u2011Amio aims to deliver amiodarone to cardiomyocytes to reduce systemic toxicity; reported in NIH STTR award news.",
      "sources": [
        "https://innovationpartnership.net/vivasc-therapeutics-awarded-nih-phi-sttr/"
      ]
    },
    {
      "id": "ap30663",
      "name": "AP30663",
      "type": "Drug",
      "category": "Rhythm Control - Antiarrhythmic Drugs",
      "stage": "Phase 2",
      "mechanism": "Intravenous SK (KCa2) ion channel inhibitor",
      "focus": "Pharmacologic cardioversion of recent-onset AF",
      "company": "Acesion Pharma",
      "latest_update": "ClinicalTrials.gov update posted 2024-05-06",
      "tags": [
        "SK channel",
        "IV",
        "cardioversion"
      ],
      "trials": [
        {
          "name": "AP30663 Phase 2",
          "phase": "Phase 2",
          "status": "COMPLETED",
          "readout": "Nature Medicine 2023",
          "readout_date": "2022-12-13",
          "registry_id": "NCT04571385",
          "note": "Recent-onset AF (\u22647 days)"
        }
      ],
      "notes": "Randomized Phase 2 showed superior cardioversion vs placebo; transient QTc prolongation reported.",
      "sources": [
        "https://www.nature.com/articles/s41591-023-02679-9",
        "https://acesionpharma.com/acesion-pharma-announces-nature-medicine-publication-of-clinical-results-in-atrial-fibrillation/",
        "https://pubmed.ncbi.nlm.nih.gov/38092897/"
      ]
    },
    {
      "id": "hbi-3000",
      "name": "HBI-3000 (sulcardine)",
      "type": "Drug",
      "category": "Rhythm Control - Antiarrhythmic Drugs",
      "stage": "Phase 2",
      "mechanism": "Intravenous multi\u2011ion channel blocker (sulcardine derivative)",
      "focus": "Pharmacologic cardioversion of recent\u2011onset AF",
      "company": "HUYABIO International",
      "latest_update": "ClinicalTrials.gov update posted 2025-12-02",
      "tags": [
        "IV",
        "cardioversion",
        "multi-ion channel"
      ],
      "trials": [
        {
          "name": "HBI-3000-402",
          "phase": "Phase 2",
          "status": "ACTIVE_NOT_RECRUITING",
          "readout": "Initial findings reported 2024-2025",
          "readout_date": "2025-12-31",
          "registry_id": "NCT04680026",
          "note": "Recent-onset AF (2\u201372 hours)"
        }
      ],
      "notes": "IV sulcardine derivative aimed at safer cardioversion; Phase 2 trial for acute AF conversion.",
      "sources": [
        "https://huyabio.com/huyabio-international-announces-initiation-of-phase-2-atrial-fibrillation-trial/",
        "https://huyabio.com/huyabio-international-announces-completion-of-hbi-3000-phase-1-trial-and-fda-approval-to-proceed-with-dose-escalation-in-phase-2/",
        "https://cdek.pharmacy.purdue.edu/trial/NCT04680026/",
        "https://huyabio.com/huyabio-validates-protective-mechanism-for-antiarrhythmic-drug-hbi-3000-in-af-patients-paving-the-way-for-a-new-era-in-atrial-fibrillation-treatment/"
      ]
    },
    {
      "id": "hbi-3020",
      "name": "HBI-3020",
      "type": "Drug",
      "category": "Rhythm Control - Antiarrhythmic Drugs",
      "stage": "Preclinical / early clinical",
      "mechanism": "Oral second\u2011generation sulcardine (multi\u2011ion channel blocker)",
      "focus": "Chronic rhythm control in AF (oral formulation)",
      "company": "HUYABIO International",
      "latest_update": "Company describes HBI\u20113020 as a second\u2011generation oral form of HBI\u20113000",
      "tags": [
        "oral",
        "multi-ion channel"
      ],
      "trials": [],
      "notes": "Oral follow\u2011on to HBI\u20113000; positioned for chronic AF control.",
      "sources": [
        "https://huyabio.com/huyabio-validates-protective-mechanism-for-antiarrhythmic-drug-hbi-3000-in-af-patients-paving-the-way-for-a-new-era-in-atrial-fibrillation-treatment/"
      ]
    },
    {
      "id": "budiodarone",
      "name": "Budiodarone",
      "type": "Drug",
      "category": "Rhythm Control - Antiarrhythmic Drugs",
      "stage": "Phase 2",
      "mechanism": "Oral antiarrhythmic related to amiodarone",
      "focus": "AF burden reduction in paroxysmal AF",
      "company": "Xyra / Lee's Pharmaceutical (prior: Armetheon)",
      "latest_update": "Phase 2 randomized trial demonstrated AF burden reduction; ongoing IP activity and development plans",
      "tags": [
        "oral",
        "AF burden",
        "AAD"
      ],
      "trials": [
        {
          "name": "Budiodarone randomized Phase 2",
          "phase": "Phase 2",
          "status": "Published",
          "readout": "AF burden reduction",
          "readout_date": "2012-01-03",
          "registry_id": null,
          "note": "Paroxysmal AF; pacemaker-monitored AT/AF burden"
        }
      ],
      "notes": "Phase 2 randomized study showed dose\u2011dependent reduction in AF burden; newer sponsors cite ongoing development.",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/22205496/",
        "https://www.prnewswire.com/news-releases/xyra-announces-the-issuance-of-a-fifth-new-us-patent-in-a-series-of-patents-which-protect-the-use-of-budiodarone-in-the-management-of-atrial-fibrillation-till-after-2040-302436581.html",
        "https://www.prnewswire.com/news-releases/armetheon-announces-issuance-of-a-new-us-patent-for-its-phase-2-clinical-stage-novel-oral-anti-arrhythmic-budiodarone-300406058.html"
      ]
    },
    {
      "id": "metoprolol",
      "name": "Metoprolol",
      "type": "Drug",
      "category": "Rate Control",
      "stage": "Approved",
      "mechanism": "Beta blocker",
      "focus": "Rate control in AF",
      "company": "Generic",
      "latest_update": "Standard rate control therapy",
      "tags": [
        "beta blocker"
      ],
      "trials": [],
      "notes": "First-line rate control agent.",
      "sources": []
    },
    {
      "id": "rapiblyk-landiolol",
      "name": "Rapiblyk (landiolol)",
      "type": "Drug",
      "category": "Rate Control - Acute AFib/AFlutter",
      "stage": "FDA Approved (Nov 22, 2024)",
      "mechanism": "Ultra-short-acting beta-1 selective blocker (IV)",
      "focus": "Short-term ventricular rate control in AF and atrial flutter (critical care)",
      "company": "AOP Health (U.S. commercial partner: Eagle Pharmaceuticals)",
      "latest_update": "FDA approval Nov 22, 2024; U.S. commercial availability announced July 21, 2025",
      "tags": [
        "beta blocker",
        "acute care",
        "IV"
      ],
      "trials": [
        {
          "name": "SVT randomized trials",
          "phase": "Pivotal",
          "status": "Completed",
          "readout": "Supported FDA approval",
          "readout_date": "2024-11-27",
          "registry_id": null,
          "note": "AF/AFlutter in critical care"
        }
      ],
      "notes": "Indicated for short-term reduction of ventricular rate in SVT including AF and atrial flutter; not for chronic arrhythmia management.",
      "sources": [
        "https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rapiblyk",
        "https://www.aop-health.com/us_en/press/press-releases/aop-health-announces-us-availability-of-rapiblyk/",
        "https://www.aop-health.com/us_en/press/press-releases/us-fda-approves-rapiblyk/"
      ]
    },
    {
      "id": "diltiazem",
      "name": "Diltiazem",
      "type": "Drug",
      "category": "Rate Control",
      "stage": "Approved",
      "mechanism": "Non-dihydropyridine calcium channel blocker",
      "focus": "Rate control in AF",
      "company": "Generic",
      "latest_update": "Standard rate control therapy",
      "tags": [
        "CCB"
      ],
      "trials": [],
      "notes": "Common option for rate control.",
      "sources": []
    },
    {
      "id": "verapamil",
      "name": "Verapamil",
      "type": "Drug",
      "category": "Rate Control",
      "stage": "Approved",
      "mechanism": "Non-dihydropyridine calcium channel blocker",
      "focus": "Rate control in AF",
      "company": "Generic",
      "latest_update": "Standard rate control therapy",
      "tags": [
        "CCB"
      ],
      "trials": [],
      "notes": "Common option for rate control.",
      "sources": []
    },
    {
      "id": "digoxin",
      "name": "Digoxin",
      "type": "Drug",
      "category": "Rate Control",
      "stage": "Approved",
      "mechanism": "Cardiac glycoside",
      "focus": "Rate control in AF",
      "company": "Generic",
      "latest_update": "Adjunctive rate control therapy",
      "tags": [
        "glycoside"
      ],
      "trials": [],
      "notes": "Often used when additional rate control is needed.",
      "sources": []
    },
    {
      "id": "praxbind",
      "name": "Praxbind (idarucizumab)",
      "type": "Drug",
      "category": "Reversal Agents",
      "stage": "FDA Approved",
      "mechanism": "Monoclonal antibody fragment that reverses dabigatran",
      "focus": "Emergency reversal of dabigatran anticoagulation",
      "company": "Boehringer Ingelheim",
      "latest_update": "FDA-approved specific reversal agent for dabigatran",
      "tags": [
        "reversal",
        "dabigatran"
      ],
      "trials": [],
      "notes": "Indicated for dabigatran reversal in emergencies or urgent procedures.",
      "sources": [
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761025s010lbl.pdf"
      ]
    },
    {
      "id": "andexxa",
      "name": "Andexxa / Andexanet alfa",
      "type": "Drug",
      "category": "Reversal Agents",
      "stage": "FDA Approved (sales stopped in US Dec 2025)",
      "mechanism": "Decoy FXa protein reversing factor Xa inhibitors",
      "focus": "Reversal of apixaban and rivaroxaban anticoagulation",
      "company": "AstraZeneca (Portola)",
      "latest_update": "U.S. sales stopped Dec 22, 2025 after FDA safety communication",
      "tags": [
        "reversal",
        "FXa inhibitors"
      ],
      "trials": [],
      "notes": "FDA issued safety communication on risk of thrombosis and mortality in 2025; manufacturer halted U.S. sales.",
      "sources": [
        "https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-safety-concerns-with-andoexxa-andexanet-alfa-treatment-reversal-anticoagulation"
      ]
    },
    {
      "id": "ciraparantag",
      "name": "Ciraparantag",
      "type": "Drug",
      "category": "Reversal Agents",
      "stage": "Phase 2",
      "mechanism": "Small-molecule anticoagulant reversal agent",
      "focus": "Reversal of DOACs and heparins",
      "company": "Perosphere (developer)",
      "latest_update": "ClinicalTrials.gov update posted 2020-05-28",
      "tags": [
        "reversal",
        "DOACs",
        "broad-spectrum"
      ],
      "trials": [
        {
          "name": "Ciraparantag edoxaban reversal",
          "phase": "Phase 2",
          "status": "COMPLETED",
          "readout": "Reversal of anticoagulation in healthy volunteers",
          "readout_date": "2013-12",
          "registry_id": "NCT01826266",
          "note": "Healthy volunteers"
        }
      ],
      "notes": "Universal reversal agent candidate evaluated in Phase 2 studies with edoxaban and enoxaparin in healthy volunteers.",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/31122798/"
      ]
    },
    {
      "id": "bms-986341",
      "name": "BMS-986341 / JNJ-77906998",
      "type": "Drug",
      "category": "Reversal Agents",
      "stage": "Phase 1",
      "mechanism": "Monoclonal antibody against FXIa inhibitor milvexian",
      "focus": "Reversal of milvexian anticoagulant activity",
      "company": "BMS / Johnson & Johnson",
      "latest_update": "Phase 1 trials in healthy participants reported; reversal of milvexian anticoagulant effect",
      "tags": [
        "reversal",
        "milvexian",
        "FXI"
      ],
      "trials": [
        {
          "name": "BMS-986341 Phase 1",
          "phase": "Phase 1",
          "status": "Reported",
          "readout": "Reversal of milvexian activity in healthy participants",
          "readout_date": "2023-06-01",
          "registry_id": null,
          "note": "Single-ascending-dose and reversal studies"
        }
      ],
      "notes": "Investigational monoclonal antibody reversal agent specific to milvexian (FXI inhibitor).",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/37225619/",
        "https://pmc.ncbi.nlm.nih.gov/articles/PMC10419996/"
      ]
    },
    {
      "id": "slounase",
      "name": "Slounase (batroxobin)",
      "type": "Drug",
      "category": "Hemostatic Agents",
      "stage": "Approved (regional)",
      "mechanism": "Thrombin-like serine protease from snake venom",
      "focus": "Hemostasis in bleeding disorders and surgery",
      "company": "Lee's Pharmaceutical",
      "latest_update": "Marketed hemostatic agent in China; limited AF-specific data",
      "tags": [
        "hemostatic",
        "batroxobin"
      ],
      "trials": [],
      "notes": "Hemostatic agent not specific to AF anticoagulant reversal; included for watchlist context.",
      "sources": [
        "https://www.leespharm.com/en/products.php?mid=5",
        "https://www.sciencedirect.com/science/article/pii/S0002944015313220"
      ]
    },
    {
      "id": "vmx-c001",
      "name": "VMX-C001",
      "type": "Drug",
      "category": "Reversal Agents",
      "stage": "Phase 3 (planned)",
      "mechanism": "Small-molecule Factor Xa inhibitor reversal",
      "focus": "Reversal of FXa inhibitors in bleeding",
      "company": "VarmX",
      "latest_update": "EquilibriX\u2011S Phase 3 study announced in 2025",
      "tags": [
        "reversal",
        "FXa inhibitors"
      ],
      "trials": [
        {
          "name": "EquilibriX-S",
          "phase": "Phase 3",
          "status": "Planned",
          "readout": "TBD",
          "readout_date": null,
          "registry_id": null,
          "note": "Severe bleeding reversal"
        }
      ],
      "notes": "Investigational reversal agent targeting FXa inhibitors; Phase 3 trial announced.",
      "sources": [
        "https://varmx.com/press/vmx-announces-phase-3-trial-for-vmx-c001/"
      ]
    },
    {
      "id": "okl-1111",
      "name": "OKL-1111",
      "type": "Drug",
      "category": "Reversal Agents",
      "stage": "Phase 1 completed (program status uncertain)",
      "mechanism": "Broad-spectrum anticoagulant reversal agent",
      "focus": "Reversal of direct thrombin and FXa inhibitors",
      "company": "Alveron",
      "latest_update": "Company stated Phase 1 was successful but subsequent data did not support progression",
      "tags": [
        "reversal",
        "program status"
      ],
      "trials": [],
      "notes": "Alveron reported Phase 1 success but later data did not support continued development.",
      "sources": [
        "https://alveron.com/news/alveron-initiates-kgk-strategic-partnership-on-lex-033/"
      ]
    },
    {
      "id": "prothromplex-total",
      "name": "Prothromplex Total (4F-PCC)",
      "type": "Drug",
      "category": "Reversal Agents",
      "stage": "Approved (EU/UK)",
      "mechanism": "Four-factor prothrombin complex concentrate",
      "focus": "Reversal of vitamin K antagonist anticoagulation",
      "company": "Takeda (Shire)",
      "latest_update": "Approved PCC for VKA reversal; SmPC maintained in UK",
      "tags": [
        "PCC",
        "VKA reversal"
      ],
      "trials": [],
      "notes": "Four-factor PCC indicated for rapid reversal of warfarin/VKA effects in major bleeding or urgent surgery.",
      "sources": [
        "https://products.mhra.gov.uk/product/?product=PL40154/0022"
      ]
    },
    {
      "id": "watchman-flx",
      "name": "WATCHMAN FLX",
      "type": "Device",
      "category": "LAA Occlusion Devices",
      "stage": "FDA Approved",
      "mechanism": "Left atrial appendage closure device",
      "focus": "Stroke prevention in non-valvular AF",
      "company": "Boston Scientific",
      "latest_update": "FDA approval for next-generation WATCHMAN FLX in 2020",
      "tags": [
        "LAAO",
        "implant"
      ],
      "trials": [
        {
          "name": "PINNACLE FLX",
          "phase": "Pivotal",
          "status": "Completed",
          "readout": "Supported FDA approval",
          "readout_date": "2020-07-23",
          "registry_id": null,
          "note": "LAAC performance"
        }
      ],
      "notes": "Indicated to reduce stroke risk in NVAF patients who need an alternative to oral anticoagulation.",
      "sources": [
        "https://www.acc.org/Latest-in-Cardiology/Articles/2020/07/23/14/14/Next-Generation-WATCHMAN-FLX-LAAC-Device-Gains-FDA-Approval"
      ]
    },
    {
      "id": "amulet",
      "name": "Amplatzer Amulet",
      "type": "Device",
      "category": "LAA Occlusion Devices",
      "stage": "FDA Approved",
      "mechanism": "Left atrial appendage occluder",
      "focus": "Stroke prevention in AF",
      "company": "Abbott",
      "latest_update": "FDA approval in 2021",
      "tags": [
        "LAAO",
        "implant"
      ],
      "trials": [
        {
          "name": "Amulet IDE",
          "phase": "Pivotal",
          "status": "Completed",
          "readout": "Supported FDA approval",
          "readout_date": "2021-08-16",
          "registry_id": null,
          "note": "LAAC vs WATCHMAN"
        }
      ],
      "notes": "FDA-approved LAA occluder for AF patients at risk of stroke.",
      "sources": [
        "https://abbott.mediaroom.com/2021-08-16-Abbotts-Amplatzer-TM-Amulet-TM-Device-Approved-by-FDA-to-Treat-People-With-Atrial-Fibrillation-at-Risk-of-Stroke"
      ]
    },
    {
      "id": "watchman-flx-pro",
      "name": "WATCHMAN FLX Pro",
      "type": "Device",
      "category": "LAA Occlusion Devices",
      "stage": "FDA Approved",
      "mechanism": "Next-generation LAA closure device with extended sizes and enhanced sealing",
      "focus": "Stroke prevention in non-valvular AF",
      "company": "Boston Scientific",
      "latest_update": "FDA approval announced Feb 2024",
      "tags": [
        "LAAO",
        "implant"
      ],
      "trials": [
        {
          "name": "PINNACLE FLX",
          "phase": "Pivotal",
          "status": "Completed",
          "readout": "Supported approvals",
          "readout_date": "2020-07-23",
          "registry_id": null,
          "note": "WATCHMAN FLX clinical program"
        }
      ],
      "notes": "FLX Pro adds 40 mm size and polymer coating for enhanced sealing.",
      "sources": [
        "https://news.bostonscientific.com/2024-02-06-Boston-Scientific-Receives-FDA-Approval-for-WATCHMAN-FLX-Pro-LAA-Closure-Device",
        "https://www.bostonscientific.com/en-US/products/laac-system/watchman-flx-pro.html"
      ]
    },
    {
      "id": "appligator",
      "name": "Appligator LAA Elimination System",
      "type": "Device",
      "category": "LAA Occlusion Devices",
      "stage": "First-in-human study initiated",
      "mechanism": "Implant-free transcatheter LAA elimination (vacuum-based)",
      "focus": "Stroke prevention in non\u2011valvular AF",
      "company": "Append Medical",
      "latest_update": "Append Medical reported FIH study kickoff and earlier funding to support the Appligator FIH study",
      "tags": [
        "LAAO",
        "implant-free",
        "FIH"
      ],
      "trials": [
        {
          "name": "Appligator First-in-Human",
          "phase": "First-in-human",
          "status": "Initiated",
          "readout": "TBD",
          "readout_date": null,
          "registry_id": null,
          "note": "Append Medical FIH study kickoff reported 2024"
        }
      ],
      "notes": "Append describes an implant-free LAA elimination system aimed at eliminating DRT/PDL risks; company news cites FIH study kickoff.",
      "sources": [
        "https://appendmedical.com/",
        "https://www.prnewswire.com/news-releases/append-medical-raises-4-35m-in-initial-closing-of-extended-series-a-round-301870942.html"
      ]
    },
    {
      "id": "sepiola-laac",
      "name": "Sepiola LAA Closure Device",
      "type": "Device",
      "category": "LAA Occlusion Devices",
      "stage": "Clinical study (safety and performance)",
      "mechanism": "LAA closure device",
      "focus": "Stroke prevention in non\u2011valvular AF",
      "company": "Endomatic",
      "latest_update": "ClinicalTrials.gov update posted 2025-08-17",
      "tags": [
        "LAAO",
        "clinical study"
      ],
      "trials": [
        {
          "name": "Sepiola safety and performance study",
          "phase": "Clinical study",
          "status": "RECRUITING",
          "readout": "TBD",
          "readout_date": "2026-06",
          "registry_id": "NCT06099106",
          "note": "Safety and performance in LAA closure"
        }
      ],
      "notes": "CenterWatch lists a safety/performance clinical study for the Sepiola LAA closure device.",
      "sources": [
        "https://www.centerwatch.com/clinical-trials/listings/NCT06099106/safety-and-performance-of-endomatic-sepiola-left-atrial-appendage-laa-closure-device"
      ]
    },
    {
      "id": "wavecrest",
      "name": "WaveCrest LAA Occluder",
      "type": "Device",
      "category": "LAA Occlusion Devices",
      "stage": "Investigational (U.S.)",
      "mechanism": "Expandable foam-based LAA occluder",
      "focus": "Stroke prevention in non-valvular AF",
      "company": "Coherex Medical (Biosense Webster)",
      "latest_update": "WaveCrest IDE study continues in U.S.",
      "tags": [
        "LAAO",
        "IDE"
      ],
      "trials": [
        {
          "name": "WaveCrest IDE",
          "phase": "Pivotal",
          "status": "Ongoing",
          "readout": "TBD",
          "readout_date": null,
          "registry_id": "NCT02813111",
          "note": "LAA occlusion"
        }
      ],
      "notes": "Investigational device in U.S. IDE; designed for full LAA sealing with proximal occlusion.",
      "sources": [
        "https://clinicaltrials.gov/study/NCT02813111"
      ]
    },
    {
      "id": "conformal-claas",
      "name": "Conformal CLAAS",
      "type": "Device",
      "category": "LAA Occlusion Devices",
      "stage": "Pivotal IDE (CONFORM)",
      "mechanism": "Conformable foam-based LAA occluder",
      "focus": "Stroke prevention in non-valvular AF",
      "company": "Conformal Medical",
      "latest_update": "ClinicalTrials.gov update posted 2026-02-10",
      "tags": [
        "LAAO",
        "foam"
      ],
      "trials": [
        {
          "name": "CONFORM Pivotal",
          "phase": "Pivotal IDE",
          "status": "RECRUITING",
          "readout": "TBD",
          "readout_date": "2028-06",
          "registry_id": "NCT05147792",
          "note": "Randomized vs approved LAAO devices"
        }
      ],
      "notes": "Conformable foam-based device; pivotal trial evaluating safety and efficacy vs approved LAAO devices.",
      "sources": [
        "https://www.conformtrial.com/conform-trial",
        "https://conformalmedical.com/company/news/conformal-medical-achieves-enrollment-milestone-in-the-conform-ide-trial"
      ]
    },
    {
      "id": "conformal-acuform",
      "name": "Conformal CLAAS AcuForm",
      "type": "Device",
      "category": "LAA Occlusion Devices",
      "stage": "Early clinical (GLACE)",
      "mechanism": "Next\u2011gen conformable foam LAA occluder",
      "focus": "Stroke prevention in non\u2011valvular AF",
      "company": "Conformal Medical",
      "latest_update": "GLACE study launched in Europe; initial clinical use highlighted at AF Symposium 2025",
      "tags": [
        "LAAO",
        "foam",
        "next-gen"
      ],
      "trials": [
        {
          "name": "GLACE",
          "phase": "Early clinical",
          "status": "Enrolling",
          "readout": "Initial clinical use highlighted",
          "readout_date": "2025-01-17",
          "registry_id": null,
          "note": "European multicenter study with ICE guidance"
        }
      ],
      "notes": "Next\u2011generation CLAAS LAA occluder with advanced foam structure and sealing.",
      "sources": [
        "https://conformalmedical.com/company/news/conformal-medical-announces-launch-of-the-glace-study-with-next-gen-claas-acuform-left-atrial-appendage-occlusion-device",
        "https://conformalmedical.com/company/news/conformal-medical-announces-glace-study-to-be-highlighted-at-af-symposium"
      ]
    },
    {
      "id": "lambr-plus",
      "name": "LAMBRE Plus LAA Occluder",
      "type": "Device",
      "category": "LAA Occlusion Devices",
      "stage": "FDA-approved investigator-initiated trial (US)",
      "mechanism": "Self-expanding LAA occluder with disc-and-lobe design",
      "focus": "Stroke prevention in non\u2011valvular AF",
      "company": "Lifetech Scientific",
      "latest_update": "FDA-approved investigator-initiated pre\u2011market clinical trial in the U.S.",
      "tags": [
        "LAAO",
        "disc-lobe"
      ],
      "trials": [],
      "notes": "Lifetech LAA occluder with CE Mark; used outside U.S.",
      "sources": [
        "https://www.prnewswire.com/news-releases/fda-approved-investigator-initiated-pre-market-clinical-trial-of-lambre-plus-laa-closure-system-obtained-medical-insurance-coverage-in-the-us-301617667.html"
      ]
    },
    {
      "id": "laminar-laax",
      "name": "Laminar LAAX System",
      "type": "Device",
      "category": "LAA Occlusion Devices",
      "stage": "Pivotal IDE enrolling",
      "mechanism": "Rotational elimination of LAA (LAAX)",
      "focus": "Stroke prevention in non\u2011valvular AF",
      "company": "Johnson & Johnson MedTech (Biosense Webster)",
      "latest_update": "Pivotal IDE enrollment began Feb 2024 following J&J acquisition of Laminar",
      "tags": [
        "LAAO",
        "LAAX",
        "pivotal"
      ],
      "trials": [
        {
          "name": "Laminar LAAX Pivotal IDE",
          "phase": "Pivotal IDE",
          "status": "Enrolling",
          "readout": "TBD",
          "readout_date": null,
          "registry_id": null,
          "note": "Randomized vs FDA-approved LAAO devices"
        }
      ],
      "notes": "Rotational LAA elimination device acquired by J&J MedTech; pivotal IDE enrollment initiated in 2024.",
      "sources": [
        "https://www.jnjmedtech.com/en-US/news-events/johnson-johnson-medtech-acquires-laminar-inc",
        "https://www.jnjmedtech.com/en-US/news-events/biosense-webster-begins-enrollment-pivotal-trial-evaluating-laminar-left-atrial"
      ]
    },
    {
      "id": "anchorman",
      "name": "AnchorMan LAAC System",
      "type": "Device",
      "category": "LAA Occlusion Devices",
      "stage": "NMPA Approved (China); EU MDR certified",
      "mechanism": "Semi-closed LAAC device with 3D folding anchors",
      "focus": "Stroke prevention in non\u2011valvular AF",
      "company": "MicroPort CardioFlow",
      "latest_update": "EU MDR approval (Mar 2025); NMPA approval in China (Jan 2024)",
      "tags": [
        "LAAO",
        "China",
        "EU MDR"
      ],
      "trials": [
        {
          "name": "SAFE PROTECT",
          "phase": "Pivotal",
          "status": "Readout",
          "readout": "12-month primary endpoint met vs Watchman",
          "readout_date": "2023-05-17",
          "registry_id": null,
          "note": "Head-to-head randomized study in China"
        }
      ],
      "notes": "Semi-closed LAAC device with clinical data and regulatory approvals in China and EU.",
      "sources": [
        "https://microport.com/news/microport-cardioflows-anchorman-left-atrial-appendage-closure-system-accelerates-its-commercial-rollout",
        "https://microport.com/news/microport-cardioflow-receives-eu-market-approval-for-anchorman",
        "https://microport.com/news/microport-s-laa-closure-anchorman-device-achieves-primary-endpoint-from-safe-protect-clinical-trial-showing-very-promising-results"
      ]
    },
    {
      "id": "seala-laac",
      "name": "SeaLA LAAC Device",
      "type": "Device",
      "category": "LAA Occlusion Devices",
      "stage": "Clinical (China)",
      "mechanism": "Pacifier-like LAA occluder",
      "focus": "Stroke prevention in non\u2011valvular AF",
      "company": "DiNovA EP",
      "latest_update": "ClinicalTrials.gov update posted 2023-06-27",
      "tags": [
        "LAAO",
        "China"
      ],
      "trials": [
        {
          "name": "SeaLA study",
          "phase": "Prospective",
          "status": "UNKNOWN",
          "readout": "12-month outcomes",
          "readout_date": "2021-01-21",
          "registry_id": "NCT05911685",
          "note": "Prospective multicenter NVAF study"
        }
      ],
      "notes": "Pacifier-like LAA occluder with published multicenter outcomes.",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/38841867/"
      ]
    },
    {
      "id": "omega-laao",
      "name": "Omega LAA Occluder",
      "type": "Device",
      "category": "LAA Occlusion Devices",
      "stage": "Early clinical",
      "mechanism": "Self-retaining inverted cup LAA occluder",
      "focus": "Stroke prevention in non\u2011valvular AF",
      "company": "Eclipse Medical",
      "latest_update": "First human data referenced in 2024 European Heart Journal review",
      "tags": [
        "LAAO",
        "early clinical"
      ],
      "trials": [],
      "notes": "Device design emphasizes stability and malleability; early human data reported in literature.",
      "sources": [
        "https://academic.oup.com/eurheartj/article/46/Supplement_1/ehaf784.537/8310137",
        "https://pubmed.ncbi.nlm.nih.gov/33034944/"
      ]
    },
    {
      "id": "zenith-laao",
      "name": "Zenith LAA Occlusion System",
      "type": "Device",
      "category": "LAA Occlusion Devices",
      "stage": "First-in-human",
      "mechanism": "LAA occluder with independent anchors and repositionability",
      "focus": "Stroke prevention in non\u2011valvular AF",
      "company": "AuriGen Medical",
      "latest_update": "First\u2011in\u2011human implantation announced",
      "tags": [
        "LAAO",
        "FIH"
      ],
      "trials": [],
      "notes": "First\u2011in\u2011human case reported by AuriGen.",
      "sources": [
        "https://aurigenmedical.com/"
      ]
    },
    {
      "id": "vine",
      "name": "Vine",
      "type": "Device",
      "category": "Stroke Prevention - Carotid Filter",
      "stage": "Investigational",
      "mechanism": "Permanent carotid artery filter for clot interception",
      "focus": "Stroke prevention in AF patients (LVO interception)",
      "company": "Javelin Medical",
      "latest_update": "CAPTURE and CAPTURE II completed; INTERCEPT randomized trial planned",
      "tags": [
        "stroke prevention",
        "filter",
        "AF"
      ],
      "trials": [
        {
          "name": "CAPTURE II",
          "phase": "Safety/performance",
          "status": "Completed",
          "readout": "Long\u2011term follow\u2011up ongoing",
          "readout_date": null,
          "registry_id": null,
          "note": "Feasibility and performance"
        },
        {
          "name": "INTERCEPT",
          "phase": "Randomized",
          "status": "Planned",
          "readout": "TBD",
          "readout_date": null,
          "registry_id": null,
          "note": "AF with recent ischemic stroke"
        }
      ],
      "notes": "Permanent carotid filter approach to stroke prevention in AF; investigational.",
      "sources": [
        "https://www.javelinmed.com/"
      ]
    },
    {
      "id": "watchman-nextgen",
      "name": "WATCHMAN Next-Generation (4th gen)",
      "type": "Device",
      "category": "LAA Occlusion Devices",
      "stage": "Planned pivotal trial (2026)",
      "mechanism": "Left atrial appendage closure device",
      "focus": "Stroke prevention in non-valvular AF",
      "company": "Boston Scientific",
      "latest_update": "Pivotal U.S. IDE trial planned to start in 2026; results expected early 2028",
      "tags": [
        "LAAO",
        "pipeline"
      ],
      "trials": [
        {
          "name": "NG WATCHMAN IDE",
          "phase": "Pivotal",
          "status": "Planned",
          "readout": "Results expected early 2028",
          "readout_date": null,
          "registry_id": null,
          "note": "Single-arm 45-day endpoint"
        }
      ],
      "notes": "Next-generation LAAO device designed for improved sealing across complex appendage anatomy.",
      "sources": [
        "https://cardiovascularbusiness.com/topics/clinical/structural-heart-disease/left-atrial-appendage-closure/next-generation-watchman-enters-trial-2026-laao-volume-grows"
      ]
    },
    {
      "id": "farapulse",
      "name": "FARAPULSE PFA System",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "FDA Approved",
      "mechanism": "Pulsed field ablation",
      "focus": "Paroxysmal and persistent AF ablation",
      "company": "Boston Scientific",
      "latest_update": "FDA approval in Jan 2024; expanded label for persistent AF in July 2025",
      "tags": [
        "PFA",
        "ablation"
      ],
      "trials": [
        {
          "name": "ADVENT",
          "phase": "Pivotal",
          "status": "Completed",
          "readout": "Supported FDA approval",
          "readout_date": "2024-01-31",
          "registry_id": null,
          "note": "PFA vs thermal ablation"
        },
        {
          "name": "ADVANTAGE AF",
          "phase": "Phase 2",
          "status": "Met endpoints",
          "readout": "Supported expanded labeling",
          "readout_date": "2025-07-07",
          "registry_id": null,
          "note": "Persistent AF"
        }
      ],
      "notes": "PFA system FDA-approved for paroxysmal AF; expanded labeling to persistent AF in 2025. Boston Scientific\u2019s FARAFLEX is referenced by the company as part of its PFA portfolio.",
      "sources": [
        "https://news.bostonscientific.com/2024-01-31-Boston-Scientific-Receives-FDA-Approval-for-FARAPULSE-TM-Pulsed-Field-Ablation-System",
        "https://news.bostonscientific.com/2025-07-07-Boston-Scientific-receives-FDA-approval-for-expanded-labeling-of-FARAPULSE-TM-Pulsed-Field-Ablation-System"
      ]
    },
    {
      "id": "pulseselect",
      "name": "PulseSelect PFA System",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "FDA Approved",
      "mechanism": "Pulsed field ablation",
      "focus": "Paroxysmal and persistent AF ablation",
      "company": "Medtronic",
      "latest_update": "FDA approval in Dec 2023",
      "tags": [
        "PFA",
        "ablation"
      ],
      "trials": [
        {
          "name": "PulseSelect IDE",
          "phase": "Pivotal",
          "status": "Completed",
          "readout": "Supported FDA approval",
          "readout_date": "2023-12-13",
          "registry_id": null,
          "note": "Paroxysmal and persistent AF"
        }
      ],
      "notes": "First PFA system to receive FDA approval.",
      "sources": [
        "https://news.medtronic.com/2023-12-13-Medtronic-creates-history-with-FDA-approval-of-its-novel-PulseSelect-TM-Pulsed-Field-Ablation-System-to-treat-atrial-fibrillation"
      ]
    },
    {
      "id": "farawave",
      "name": "FARAWAVE PFA Catheter",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "FDA Approved (as part of FARAPULSE)",
      "mechanism": "Single-shot multielectrode PFA catheter (basket/flower shapes)",
      "focus": "Pulmonary vein isolation in AF",
      "company": "Boston Scientific",
      "latest_update": "FDA approval with FARAPULSE system supported by ADVENT pivotal trial",
      "tags": [
        "PFA",
        "catheter",
        "single-shot"
      ],
      "trials": [
        {
          "name": "ADVENT",
          "phase": "Pivotal",
          "status": "Completed",
          "readout": "12-month results supported FDA approval",
          "readout_date": "2024-01-31",
          "registry_id": null,
          "note": "FARAWAVE catheter within FARAPULSE system"
        }
      ],
      "notes": "FARAWAVE is the ablation catheter used in the FARAPULSE system; variable basket/flower configurations adapt to PV anatomy.",
      "sources": [
        "https://news.bostonscientific.com/2024-01-31-Boston-Scientific-Receives-FDA-Approval-for-FARAPULSE-TM-Pulsed-Field-Ablation-System",
        "https://www.acc.org/latest-in-cardiology/articles/2024/01/31/17/59/fda-update-agency-approves-farapulse-pulsed-field-ablation-system"
      ]
    },
    {
      "id": "iclas",
      "name": "iCLAS Cryoablation System",
      "type": "Device",
      "category": "Catheter Ablation - Cryoablation",
      "stage": "CE Mark; U.S. IDE",
      "mechanism": "Ultra-low temperature cryoablation (ULTC)",
      "focus": "Persistent AF ablation",
      "company": "Adagio Medical",
      "latest_update": "ClinicalTrials.gov update posted 2024-04-24",
      "tags": [
        "cryoablation",
        "ULTC"
      ],
      "trials": [
        {
          "name": "iCLAS U.S. IDE",
          "phase": "IDE",
          "status": "UNKNOWN",
          "readout": "TBD",
          "readout_date": "2023-08-30",
          "registry_id": "NCT04061603",
          "note": "Persistent AF"
        }
      ],
      "notes": "Single-catheter ultra-low temperature cryoablation system for AF; evaluated in U.S. IDE for persistent AF.",
      "sources": [
        "https://www.prnewswire.com/news-releases/adagio-medical-announces-first-patient-enrollment-in-its-iclas-us-ide-clinical-trial-evaluating-ultra-low-temperature-cryoablation-for-persistent-atrial-fibrillation-300975675.html",
        "https://www.prnewswire.com/news-releases/adagio-medical-announces-initiation-and-first-patient-enrollment-in-paralell-trial-to-investigate-safety-and-performance-of-cryopulse-catheter-system-for-pulsed-field-ablation-and-pulsed-field-cryoablation-of-persistent-atrial-fi-301657139.html"
      ]
    },
    {
      "id": "adagio-cryopulse",
      "name": "CryoPulse PFCA Catheter System",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "Early clinical",
      "mechanism": "Pulsed field ablation and pulsed field cryoablation (PFCA)",
      "focus": "Persistent AF ablation",
      "company": "Adagio Medical",
      "latest_update": "PARALELL trial initiated; first patient enrolled",
      "tags": [
        "PFA",
        "PFCA",
        "cryo"
      ],
      "trials": [
        {
          "name": "PARALELL",
          "phase": "Early clinical",
          "status": "First patient enrolled",
          "readout": "TBD",
          "readout_date": null,
          "registry_id": null,
          "note": "PFA + PFCA in persistent AF"
        }
      ],
      "notes": "Evaluates Adagio's CryoPulse catheter system using pulsed field ablation and pulsed field cryoablation.",
      "sources": [
        "https://www.prnewswire.com/news-releases/adagio-medical-announces-initiation-and-first-patient-enrollment-in-paralell-trial-to-investigate-safety-and-performance-of-cryopulse-catheter-system-for-pulsed-field-ablation-and-pulsed-field-cryoablation-of-persistent-atrial-fi-301657139.html"
      ]
    },
    {
      "id": "episense",
      "name": "EPi-Sense System",
      "type": "Device",
      "category": "Hybrid/Surgical Ablation",
      "stage": "FDA Approved",
      "mechanism": "Epicardial RF ablation (hybrid convergent procedure)",
      "focus": "Persistent and long-standing persistent AF",
      "company": "AtriCure",
      "latest_update": "ClinicalTrials.gov update posted 2023-11-13",
      "tags": [
        "RF",
        "hybrid",
        "surgical"
      ],
      "trials": [
        {
          "name": "CONVERGE",
          "phase": "Pivotal",
          "status": "COMPLETED",
          "readout": "Superiority vs endocardial ablation alone",
          "readout_date": "2019-08",
          "registry_id": "NCT01984346",
          "note": "Hybrid AF therapy"
        }
      ],
      "notes": "Epicardial ablation system used in the convergent hybrid AF procedure; FDA-approved for long-standing persistent AF.",
      "sources": [
        "https://ir.atricure.com/news-releases/news-release-details/atricures-epi-sense-system-approved-fda-treatment-long-standing",
        "https://www.atricure.com/patients-caregivers/clinical-evidence/trials-results"
      ]
    },
    {
      "id": "omnypulse",
      "name": "OMNYPULSE Platform",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "Investigational",
      "mechanism": "Large-tip focal PFA catheter platform",
      "focus": "Paroxysmal AF ablation",
      "company": "Biosense Webster (J&J MedTech)",
      "latest_update": "Omny-IRE clinical trial completed enrollment in Europe and Canada (2024)",
      "tags": [
        "PFA",
        "focal"
      ],
      "trials": [
        {
          "name": "Omny-IRE",
          "phase": "Prospective",
          "status": "Enrollment complete",
          "readout": "TBD",
          "readout_date": null,
          "registry_id": null,
          "note": "Europe and Canada; paroxysmal AF"
        }
      ],
      "notes": "Investigational focal PFA platform evaluated in Omny-IRE clinical trial.",
      "sources": [
        "https://www.jnjmedtech.com/en-US/news-events/biosense-webster-completes-enrollment-omny-ire-clinical-trial-investigating-omnypulse"
      ]
    },
    {
      "id": "tactiflex",
      "name": "TactiFlex Ablation Catheter, Sensor Enabled",
      "type": "Device",
      "category": "Catheter Ablation - RF",
      "stage": "FDA Approved",
      "mechanism": "Contact-force RF ablation catheter with flexible tip",
      "focus": "Paroxysmal AF and typical atrial flutter",
      "company": "Abbott",
      "latest_update": "FDA approval (May 18, 2023)",
      "tags": [
        "RF",
        "contact force"
      ],
      "trials": [
        {
          "name": "TactiFlex PAF IDE",
          "phase": "Pivotal",
          "status": "Completed",
          "readout": "Supported FDA approval",
          "readout_date": "2023-05-18",
          "registry_id": null,
          "note": "Paroxysmal AF"
        }
      ],
      "notes": "Flexible-tip contact-force RF ablation catheter indicated for paroxysmal AF.",
      "sources": [
        "https://www.fda.gov/medical-devices/recently-approved-devices/tactiflex-ablation-catheter-sensor-enabled-p220013",
        "https://abbott.mediaroom.com/2023-05-19-Abbott-Receives-FDA-Approval-for-TactiFlex-TM-Ablation-Catheter-for-Treatment-of-Abnormal-Heart-Rhythm"
      ]
    },
    {
      "id": "heliostar",
      "name": "HELIOSTAR Balloon Ablation Catheter",
      "type": "Device",
      "category": "Catheter Ablation - RF",
      "stage": "CE Mark (not US-approved)",
      "mechanism": "Multi-electrode RF balloon ablation",
      "focus": "Paroxysmal AF pulmonary vein isolation",
      "company": "Biosense Webster (J&J MedTech)",
      "latest_update": "STELLAR study data presented at AF Symposium 2023; CE Mark in EMEA",
      "tags": [
        "RF",
        "balloon",
        "CARTO"
      ],
      "trials": [
        {
          "name": "STELLAR",
          "phase": "Prospective",
          "status": "Presented",
          "readout": "AF Symposium 2023 data",
          "readout_date": "2023-02-03",
          "registry_id": null,
          "note": "Paroxysmal AF"
        },
        {
          "name": "RADIANCE",
          "phase": "First-in-man",
          "status": "Completed",
          "readout": "12-month outcomes published",
          "readout_date": "2020-06-01",
          "registry_id": null,
          "note": "HELIOSTAR RF balloon"
        }
      ],
      "notes": "RF balloon catheter integrated with CARTO 3; not approved in the U.S.",
      "sources": [
        "https://www.jnjmedtech.com/en-US/news-events/late-breaking-data-pulmonary-vein-isolation-heliostar-balloon-ablation-catheter",
        "https://pubmed.ncbi.nlm.nih.gov/32250514/",
        "https://citoday.com/news/biosense-websters-heliostar-radiofrequency-balloon-ablation-catheter-launched-in-europe"
      ]
    },
    {
      "id": "kardium-globe",
      "name": "Globe Pulsed Field System",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "FDA Approved (PMA)",
      "mechanism": "Single-shot spherical multielectrode PFA with integrated mapping",
      "focus": "Paroxysmal AF ablation",
      "company": "Kardium",
      "latest_update": "FDA PMA approval announced Sept 3, 2025; PULSAR IDE 1-year results presented at HRS 2025",
      "tags": [
        "PFA",
        "single-shot",
        "mapping"
      ],
      "trials": [
        {
          "name": "PULSAR IDE",
          "phase": "Pivotal",
          "status": "Readout",
          "readout": "1-year results announced",
          "readout_date": "2025-04-25",
          "registry_id": null,
          "note": "Paroxysmal AF"
        }
      ],
      "notes": "Single catheter provides mapping and ablation; PMA submission based on PULSAR IDE.",
      "sources": [
        "https://kardium.com/news/kardium-receives-fda-approval-of-the-globe-pulsed-field-system/",
        "https://kardium.com/news/kardium-announces-1-year-pulsar-ide-study-results-for-its-pfa-device-the-globe-pf-system/",
        "https://kardium.com/news/kardium-announces-completion-of-paroxysmal-enrollment-in-the-pulsar-ide-study/"
      ]
    },
    {
      "id": "optishot",
      "name": "OptiShot PFA Balloon System",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "Investigational",
      "mechanism": "Compliant PFA balloon for single-shot PVI",
      "focus": "Paroxysmal AF ablation",
      "company": "CardioFocus",
      "latest_update": "First patients treated; VISION AF clinical study underway",
      "tags": [
        "PFA",
        "balloon",
        "single-shot"
      ],
      "trials": [
        {
          "name": "VISION AF",
          "phase": "Clinical study",
          "status": "Ongoing",
          "readout": "First patients treated (Dec 2024)",
          "readout_date": "2024-12-17",
          "registry_id": null,
          "note": "OptiShot PFA"
        }
      ],
      "notes": "Investigational PFA balloon system; early human procedures completed.",
      "sources": [
        "https://www.businesswire.com/news/home/20241217582090/en/CardioFocus-Announces-First-Patients-Treated-with-OptiShot-Pulsed-Field-Ablation-System"
      ]
    },
    {
      "id": "quickshot",
      "name": "QuickShot PFA System",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "Clinical (CE Mark trial)",
      "mechanism": "Large-area focal PFA catheter",
      "focus": "AF ablation (focal PFA)",
      "company": "CardioFocus (acquired Galvanize EP division)",
      "latest_update": "First enrollments in CE Mark clinical trial announced (Nov 2025)",
      "tags": [
        "PFA",
        "focal"
      ],
      "trials": [
        {
          "name": "QuickShot CE Mark study",
          "phase": "Clinical",
          "status": "First enrollments",
          "readout": "TBD",
          "readout_date": null,
          "registry_id": null,
          "note": "QuickShot PFA catheter + CardioWave system"
        }
      ],
      "notes": "QuickShot originated from Galvanize; now developed by CardioFocus alongside CardioWave platform.",
      "sources": [
        "https://www.businesswire.com/news/home/20251111991136/en/CardioFocus-Announces-First-Enrollments-in-CE-Mark-Clinical-Trial-of-QuickShot-PFA-Catheter-and-CardioWave-PFA-System",
        "https://www.prnewswire.com/news-releases/cardiofocus-acquires-electrophysiology-division-of-galvanize-therapeutics-302031956.html"
      ]
    },
    {
      "id": "heartlight-x4",
      "name": "HeartLight X4 PFA Balloon",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "Planned human trials",
      "mechanism": "PFA balloon for single-shot PVI",
      "focus": "AF ablation",
      "company": "CardioFocus",
      "latest_update": "Expected to begin human trials in 2024 (per acquisition announcement)",
      "tags": [
        "PFA",
        "balloon"
      ],
      "trials": [
        {
          "name": "HeartLight X4",
          "phase": "Planned",
          "status": "Planned",
          "readout": "TBD",
          "readout_date": null,
          "registry_id": null,
          "note": "Planned first-in-human"
        }
      ],
      "notes": "PFA balloon program referenced in CardioFocus acquisition of Galvanize EP division.",
      "sources": [
        "https://www.prnewswire.com/news-releases/cardiofocus-acquires-electrophysiology-division-of-galvanize-therapeutics-302031956.html"
      ]
    },
    {
      "id": "ablaview",
      "name": "AblaView PFA System",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "First-in-man completed",
      "mechanism": "Optically guided PFA with optical coherence reflectometry",
      "focus": "AF ablation",
      "company": "MedLumics",
      "latest_update": "FIM study completed; 3-month remapping data presented at AF Symposium 2025",
      "tags": [
        "PFA",
        "optical guidance"
      ],
      "trials": [
        {
          "name": "AblaView FIM",
          "phase": "First-in-man",
          "status": "Completed",
          "readout": "AF Symposium 2025 late-breaking",
          "readout_date": "2025-01-17",
          "registry_id": null,
          "note": "3-month remapping"
        }
      ],
      "notes": "Optically guided PFA system with real-time OCR feedback to confirm lesion creation.",
      "sources": [
        "https://www.businesswire.com/news/home/20241219716668/en/MedLumics-is-Proud-to-Announce-the-Completion-of-the-FIM-Study-With-Successful-Remapping-at-3-Months-Demonstrating-the-Efficacy-of-the-AblaView-Optically-Guided-Pulsed-Field-Ablation-PFA-System-and-Presentation-at-the-AF-Symposium-2025"
      ]
    },
    {
      "id": "encompass-dual-energy",
      "name": "EnCompass Dual Energy Platform",
      "type": "Device",
      "category": "Surgical Ablation - Dual Energy",
      "stage": "First patients treated",
      "mechanism": "Surgical clamp with advanced RF + PFA",
      "focus": "Concomitant surgical AF ablation",
      "company": "AtriCure",
      "latest_update": "First patients treated with novel dual energy platform (Dec 2025)",
      "tags": [
        "PFA",
        "RF",
        "surgical"
      ],
      "trials": [
        {
          "name": "Dual Energy Platform",
          "phase": "Early clinical",
          "status": "First patients treated",
          "readout": "TBD",
          "readout_date": "2025-12-11",
          "registry_id": null,
          "note": "Box lesion with simultaneous PV + posterior wall isolation"
        }
      ],
      "notes": "Builds on EnCompass clamp; combines advanced RF and PFA to reduce ablation time.",
      "sources": [
        "https://www.businesswire.com/news/home/20251211833575/en/AtriCure-Announces-the-First-Patients-Treated-with-Novel-Dual-Energy-Platform"
      ]
    },
    {
      "id": "cardiopulse-dinova",
      "name": "CardiPulse PFA System",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "Clinical (China)",
      "mechanism": "Hexaspline PFA catheter with bipolar biphasic pulses",
      "focus": "Paroxysmal AF ablation (PVI)",
      "company": "Hangzhou DiNovA EP Technology",
      "latest_update": "PLEASE-AF study published with 12-month outcomes",
      "tags": [
        "PFA",
        "hexaspline",
        "China"
      ],
      "trials": [
        {
          "name": "PLEASE-AF",
          "phase": "Prospective",
          "status": "Published",
          "readout": "12-month outcomes",
          "readout_date": "2024-07-01",
          "registry_id": null,
          "note": "Single-arm PVI in paroxysmal AF"
        }
      ],
      "notes": "Hexaspline PFA system evaluated in the PLEASE-AF study with favorable 12-month efficacy and safety.",
      "sources": [
        "https://academic.oup.com/europace/article/26/7/euae174/7697849"
      ]
    },
    {
      "id": "insightpfa-lotospfa",
      "name": "LotosPFA Catheter (InsightPFA)",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "Clinical (China)",
      "mechanism": "Nanosecond biphasic PFA catheter",
      "focus": "Paroxysmal AF ablation (PVI)",
      "company": "Insight Medtech",
      "latest_update": "ClinicalTrials.gov update posted 2025-08-17",
      "tags": [
        "nsPFA",
        "PFA",
        "RCT"
      ],
      "trials": [
        {
          "name": "InsightPFA",
          "phase": "Randomized trial",
          "status": "COMPLETED",
          "readout": "Noninferior vs RFA at 12 months",
          "readout_date": "2025-06-09",
          "registry_id": "NCT06014996",
          "note": "nsPFA vs RFA for PVI"
        }
      ],
      "notes": "Randomized multicenter trial of a nanosecond PFA catheter demonstrated noninferior efficacy versus AI-guided RFA.",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/41338842/",
        "https://insight-med.com/new/215.html"
      ]
    },
    {
      "id": "arga-coherent",
      "name": "Coherent Sine-Burst Electroporation (CSE) System",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "IDE pivotal trial",
      "mechanism": "Coherent Sine-Burst Electroporation (CSE) pulsed field system",
      "focus": "Paroxysmal and persistent AF ablation",
      "company": "Arg\u00e1 Medtech",
      "latest_update": "COHERENT-AF IDE trial first enrollments announced (Sep 18, 2025)",
      "tags": [
        "PFA",
        "IDE",
        "CSE"
      ],
      "trials": [
        {
          "name": "COHERENT-AF",
          "phase": "IDE pivotal",
          "status": "Enrolling",
          "readout": "TBD",
          "readout_date": null,
          "registry_id": null,
          "note": "Paroxysmal and persistent AF"
        }
      ],
      "notes": "Second-generation PFA system evaluated in a U.S. and EU IDE pivotal study.",
      "sources": [
        "https://www.prnewswire.com/news-releases/arga-medtech-announces-first-enrollments-in-coherent-af-ide-clinical-trial-302561053.html"
      ]
    },
    {
      "id": "microport-pulsemagic",
      "name": "PulseMagic TrueForce PFA Catheter",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "Approved (China NMPA)",
      "mechanism": "Pressure-sensing PFA catheter with irrigation",
      "focus": "AF ablation (multi-energy EP platform)",
      "company": "MicroPort EP",
      "latest_update": "NMPA approval and launch in China (Nov 2025)",
      "tags": [
        "PFA",
        "China",
        "pressure sensing"
      ],
      "trials": [],
      "notes": "Part of MicroPort's multi-energy platform integrating cryoablation, RF, and PFA.",
      "sources": [
        "https://microport.com/news/microport-ep-launches-pressure-sensing-pulsed-field-ablation-catheter-expanding-its-multi-energy-platform"
      ]
    },
    {
      "id": "microport-multi-energy",
      "name": "MicroPort EP Multi\u2011Energy Platform (RF + PFA)",
      "type": "Device",
      "category": "Catheter Ablation - Platform",
      "stage": "Commercial (China); expanding",
      "mechanism": "Integrated EP platform supporting RF, cryo, and PFA technologies",
      "focus": "AF ablation across energy modalities",
      "company": "MicroPort EP",
      "latest_update": "Company highlights multi\u2011energy platform expansion with PFA and RF systems",
      "tags": [
        "platform",
        "RF",
        "PFA",
        "cryo"
      ],
      "trials": [],
      "notes": "Platform integrates multiple ablation energy sources for AF; includes RF and PFA catheters in portfolio.",
      "sources": [
        "https://microport.com/news/microport-ep-launches-pressure-sensing-pulsed-field-ablation-catheter-expanding-its-multi-energy-platform",
        "https://microport.com/news/microport-ep-showcases-innovations-at-ehra-2025-advancing-precision-in-electrophysiology"
      ]
    },
    {
      "id": "spherepvi",
      "name": "SpherePVI Multi-Ablation System",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "Investigational (U.S.); clinical studies",
      "mechanism": "Expandable lattice PFA catheter with multiple configurations",
      "focus": "Paroxysmal AF ablation",
      "company": "Affera / Medtronic",
      "latest_update": "ClinicalTrials.gov update posted 2026-02-13",
      "tags": [
        "PFA",
        "Affera",
        "single-shot"
      ],
      "trials": [
        {
          "name": "SpherePVI",
          "phase": "Prospective",
          "status": "RECRUITING",
          "readout": "One-year outcomes published",
          "readout_date": "2027-03-15",
          "registry_id": "NCT05144503",
          "note": "Safety and performance"
        }
      ],
      "notes": "Expandable lattice catheter designed for PVI; investigated in SpherePVI studies.",
      "sources": [
        "https://www.medtronic.com/en-us/e/healthcare-professionals/cardiac-ablation/sphere-360-clinical-evidence.html",
        "https://academic.oup.com/europace/article/25/4/1369/7041604"
      ]
    },
    {
      "id": "sirona-smt",
      "name": "SMT Multimodal PFA/RF Catheter",
      "type": "Device",
      "category": "Catheter Ablation - PFA/RF",
      "stage": "Preclinical / emerging",
      "mechanism": "Multimodal array with focal, oval/circular, and flat configurations; PFA + RF",
      "focus": "AF ablation",
      "company": "Sirona Medical Technologies",
      "latest_update": "Described in 2024 review of emerging ablation tools",
      "tags": [
        "PFA",
        "RF",
        "multimodal"
      ],
      "trials": [],
      "notes": "Emerging multimodal SMT catheter with adjustable diameter and rotating mechanism for contiguous lesions.",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/38304094/"
      ]
    },
    {
      "id": "atrian-atrian",
      "name": "AtriAN Epicardial PFA Catheter",
      "type": "Device",
      "category": "Cardioneuroablation - PFA",
      "stage": "Preclinical / early clinical",
      "mechanism": "Epicardial PFA targeting ganglionated plexi",
      "focus": "AF (autonomic modulation)",
      "company": "Atrian Medical",
      "latest_update": "Preclinical and early clinical evidence for epicardial GP ablation; technology described in 2024 Bioengineering paper",
      "tags": [
        "PFA",
        "epicardial",
        "GP ablation"
      ],
      "trials": [],
      "notes": "Epicardial cardioneuroablation using PFA to target ganglionated plexi; early clinical experience reported.",
      "sources": [
        "https://atrianmedical.com/epicardial-pulsed-field-ablation-for-the-treatment-of-paroxysmal-atrial-fibrillation-during-cardiac-surgery/",
        "https://atrianmedical.com/epicardial-pulsed-field-ablation-of-ganglionated-plexi-computational-and-pre-clinical-evaluation-of-a-bipolar-sub-xiphoid-catheter-for-the-treatment-of-atrial-fibrillation/",
        "https://pubmed.ncbi.nlm.nih.gov/38247895/"
      ]
    },
    {
      "id": "varipulse",
      "name": "VARIPULSE Platform",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "FDA Approved",
      "mechanism": "Pulsed field ablation",
      "focus": "Paroxysmal AF ablation",
      "company": "Johnson & Johnson MedTech",
      "latest_update": "FDA approval in Nov 2024; U.S. sales paused due to reported neurovascular events",
      "tags": [
        "PFA",
        "ablation"
      ],
      "trials": [
        {
          "name": "admIRE",
          "phase": "Pivotal",
          "status": "Completed",
          "readout": "Supported FDA approval",
          "readout_date": "2024-11-07",
          "registry_id": null,
          "note": "Paroxysmal AF"
        }
      ],
      "notes": "FDA approval for paroxysmal AF; reports of neurovascular events prompted a U.S. sales pause in 2025.",
      "sources": [
        "https://www.jnj.com/media-center/press-releases/johnson-johnson-medtech-receives-fda-approval-for-the-varipulse-pulsed-field-ablation-platform-for-the-treatment-of-atrial-fibrillation",
        "https://www.wsj.com/health/healthcare/j-js-high-hopes-for-heart-rhythm-device-grounded-by-safety-concerns-8ea63120"
      ]
    },
    {
      "id": "volt",
      "name": "Volt PFA System",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "FDA Approved",
      "mechanism": "Pulsed field ablation",
      "focus": "AF ablation",
      "company": "Abbott",
      "latest_update": "12-month Volt-AF IDE results presented at AF Symposium 2026 and published in JACC: Clinical Electrophysiology",
      "press_2026": true,
      "tags": [
        "PFA",
        "ablation"
      ],
      "trials": [
        {
          "name": "VOLT-AF IDE",
          "phase": "Pivotal",
          "status": "Completed",
          "readout": "12-month results presented at AF Symposium 2026",
          "readout_date": "2026-02-06",
          "registry_id": null,
          "note": "PFA system"
        }
      ],
      "notes": "FDA-approved PFA system; late-breaking 12-month data shared at AF Symposium 2026.",
      "sources": [
        "https://abbott.mediaroom.com/2025-12-22-Abbotts-Volt-TM-Pulsed-Field-Ablation-System-Receives-FDA-Approval-to-Treat-Patients-with-Atrial-Fibrillation",
        "https://abbott.mediaroom.com/2026-02-06-Late-breaking-data-presentations-showcase-the-safety-and-efficacy-of-Abbotts-ablation-catheters-to-treat-people-with-atrial-fibrillation"
      ]
    },
    {
      "id": "sphere-360",
      "name": "Sphere-360 PFA Catheter (Affera)",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "CE Mark; U.S. IDE",
      "mechanism": "Single-shot PFA mapping and ablation catheter",
      "focus": "Paroxysmal AF ablation",
      "company": "Medtronic",
      "latest_update": "ClinicalTrials.gov update posted 2026-02-13",
      "press_2026": true,
      "tags": [
        "PFA",
        "Affera",
        "single-shot"
      ],
      "trials": [
        {
          "name": "Horizon 360 IDE",
          "phase": "Pivotal",
          "status": "IDE first cases",
          "readout": "TBD",
          "readout_date": null,
          "registry_id": null,
          "note": "Paroxysmal AF; U.S. IDE"
        },
        {
          "name": "Sphere-360 European study",
          "phase": "Prospective",
          "status": "RECRUITING",
          "readout": "One-year results presented at HRS 2025",
          "readout_date": "2027-03-15",
          "registry_id": "NCT05115214",
          "note": "Single-arm European study"
        }
      ],
      "notes": "Rotation-free single-shot PFA catheter integrated with the Affera mapping and ablation system.",
      "sources": [
        "https://news.medtronic.com/2026-01-23-Affera-TM-momentum-continues-as-Medtronic-announces-CE-Mark-in-Europe-and-U-S-IDE-first-cases-for-Sphere-360-TM-PFA-catheter-to-treat-paroxysmal-atrial-fibrillation",
        "https://www.medtronic.com/en-us/e/healthcare-professionals/cardiac-ablation/sphere-360-clinical-evidence.html"
      ]
    },
    {
      "id": "fieldforce",
      "name": "FieldForce PFA System",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "Early clinical",
      "mechanism": "High-voltage focal PFA catheter",
      "focus": "AF ablation; focal point-by-point",
      "company": "Field Medical",
      "latest_update": "Field PULSE first-in-human data presented as late-breaking clinical trial at AF Symposium 2026",
      "press_2026": true,
      "tags": [
        "PFA",
        "focal",
        "first-in-human"
      ],
      "trials": [
        {
          "name": "Field PULSE",
          "phase": "First-in-human",
          "status": "Presented",
          "readout": "Late-breaking data at AF Symposium 2026",
          "readout_date": "2026-02-05",
          "registry_id": null,
          "note": "High-voltage waveform; point-by-point ablation"
        }
      ],
      "notes": "FieldForce system is a focal, contact-sensing PFA catheter designed for rapid point-by-point ablation.",
      "sources": [
        "https://www.prnewswire.com/news-releases/field-medical-presents-late-breaking-field-pulse-trial-data-at-af-symposium-2026-302680633.html"
      ]
    },
    {
      "id": "easy-pulz",
      "name": "Easy Pulz",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "Preclinical / early development",
      "mechanism": "Pulsed field ablation system",
      "focus": "AF ablation",
      "company": "BTL",
      "latest_update": "Company describes Easy Pulz as an emerging PFA program",
      "tags": [
        "PFA",
        "early"
      ],
      "trials": [],
      "notes": "BTL describes Easy Pulz as a PFA program aimed at AF treatment; clinical details not yet public.",
      "sources": [
        "https://www.btlnet.com/news/a-new-hope-for-atrial-fibrillation-patients"
      ]
    },
    {
      "id": "cellfx-nspfa-360",
      "name": "CellFX nsPFA 360 Cardiac Catheter",
      "type": "Device",
      "category": "Catheter Ablation - PFA",
      "stage": "First-in-human",
      "mechanism": "Nanosecond pulsed field ablation (nsPFA)",
      "focus": "AF ablation; pulmonary vein isolation",
      "company": "Pulse Biosciences",
      "latest_update": "ClinicalTrials.gov update posted 2026-01-12",
      "press_2026": true,
      "tags": [
        "nsPFA",
        "first-in-human",
        "PFA"
      ],
      "trials": [
        {
          "name": "CellFX nsPFA 360 feasibility",
          "phase": "First-in-human",
          "status": "RECRUITING",
          "readout": "AF Symposium 2026 late-breaking data",
          "readout_date": "2026-03-25",
          "registry_id": "NCT06696170",
          "note": "First-in-human feasibility study"
        }
      ],
      "notes": "Nanosecond PFA 360 catheter designed for single-shot, circumferential ablation.",
      "sources": [
        "https://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-announces-first-human-procedures-its-novel",
        "https://www.nasdaq.com/press-release/pulse-biosciences-presents-late-breaking-data-npulsetm-cardiac-catheter-system-first"
      ]
    },
    {
      "id": "cellfx-nspfa-surgery",
      "name": "CellFX nsPFA Cardiac Surgery System (NANOCLAMP AF)",
      "type": "Device",
      "category": "Surgical Ablation - PFA",
      "stage": "IDE approved (U.S.)",
      "mechanism": "Nanosecond PFA surgical clamp system",
      "focus": "Concomitant surgical AF ablation",
      "company": "Pulse Biosciences",
      "latest_update": "ClinicalTrials.gov update posted 2026-01-12",
      "tags": [
        "nsPFA",
        "surgical",
        "IDE"
      ],
      "trials": [
        {
          "name": "NANOCLAMP AF",
          "phase": "Not applicable",
          "status": "RECRUITING",
          "readout": "TBD",
          "readout_date": "2027-04",
          "registry_id": "NCT06959121",
          "note": "Concomitant cardiac surgery"
        }
      ],
      "notes": "IDE-approved U.S. study for surgical nsPFA clamp system during concomitant cardiac surgery.",
      "sources": [
        "https://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-announces-fda-ide-approval-initiate-its-nspfa",
        "https://clinicaltrials.gov/study/NCT06959121"
      ]
    },
    {
      "id": "cala-neuromod",
      "name": "Cala Peripheral Nerve Stimulation (AFib-01)",
      "type": "Device",
      "category": "Neuromodulation - Peripheral Nerve Stimulation",
      "stage": "Feasibility study",
      "mechanism": "Wrist- and ear-worn neuromodulation targeting peripheral nerves",
      "focus": "AF burden reduction",
      "company": "Cala Health",
      "latest_update": "ClinicalTrials.gov update posted 2023-02-08",
      "tags": [
        "neuromodulation",
        "wearable",
        "AF burden"
      ],
      "trials": [
        {
          "name": "AFIB-01",
          "phase": "Not applicable",
          "status": "UNKNOWN",
          "readout": "Results not posted",
          "readout_date": "2023-12",
          "registry_id": "NCT05653583",
          "note": "Wrist, ear, and sham devices"
        }
      ],
      "notes": "Randomized, sham-controlled feasibility study using wearable neuromodulation devices to reduce AF burden.",
      "sources": [
        "https://clinicaltrials.gov/study/NCT05653583"
      ]
    },
    {
      "id": "botox-poaf",
      "name": "Botulinum toxin type A (AGN-151607) for POAF prevention",
      "type": "Drug",
      "category": "Neuromodulation - Autonomic Modulation",
      "stage": "Completed trial (NOVA)",
      "mechanism": "Injection into epicardial fat pads / ganglionated plexi",
      "focus": "Prevention of post-operative AF (POAF)",
      "company": "Allergan (AbbVie) / academic investigators",
      "latest_update": "ClinicalTrials.gov update posted 2024-05-14",
      "tags": [
        "botulinum toxin",
        "POAF",
        "ganglionated plexi"
      ],
      "trials": [
        {
          "name": "NOVA",
          "phase": "Phase 1/2/3/4",
          "status": "COMPLETED",
          "readout": "Trial completed; results status varies by registry",
          "readout_date": "2022-03-24",
          "registry_id": "NCT03779841",
          "note": "Open-chest cardiac surgery patients"
        }
      ],
      "notes": "Botulinum toxin injections into epicardial fat pads studied for POAF prevention; not specific to chronic AF management.",
      "sources": [
        "https://patientsatheart.com/trials/nct03779841",
        "https://pubmed.ncbi.nlm.nih.gov/21659633/"
      ]
    },
    {
      "id": "inomagen-gene",
      "name": "Inomagen non\u2011viral gene therapy program",
      "type": "Drug",
      "category": "Gene Therapy",
      "stage": "Preclinical / IND\u2011enabling",
      "mechanism": "Non\u2011viral gene therapy targeting AF molecular mechanisms; electroporation\u2011assisted delivery",
      "focus": "Disease modification for atrial fibrillation",
      "company": "Inomagen Therapeutics",
      "latest_update": "Preclinical success in large animal models; advancing into IND\u2011enabling studies",
      "tags": [
        "gene therapy",
        "non\u2011viral",
        "IND\u2011enabling"
      ],
      "trials": [],
      "notes": "Company reports preclinical efficacy in large animal models and readiness for IND\u2011enabling studies.",
      "sources": [
        "https://inomagen.com/genetherapy",
        "https://inomagen.com/investors"
      ]
    },
    {
      "id": "cardurion-camkii",
      "name": "Cardurion CaMKII inhibitors",
      "type": "Drug",
      "category": "Disease Modification - CaMKII Inhibition",
      "stage": "Phase 1 (CPVT); AF planned",
      "mechanism": "CaMKII inhibition to normalize calcium signaling",
      "focus": "Arrhythmias including potential post-operative AF programs",
      "company": "Cardurion Pharmaceuticals",
      "latest_update": "Company cites CaMKII inhibition for arrhythmias including post-operative AF; Phase 1 ongoing in CPVT",
      "tags": [
        "CaMKII",
        "arrhythmia",
        "disease modification"
      ],
      "trials": [],
      "notes": "Cardurion describes CaMKII inhibition as relevant to arrhythmias including post-operative AF; AF programs are planned beyond initial rare arrhythmia studies.",
      "sources": [
        "https://cardurion.com/our-science/camkii/",
        "https://cardurion.com/"
      ]
    },
    {
      "id": "as-100283",
      "name": "AS-100283",
      "type": "Drug",
      "category": "Disease Modification - CaMKII Inhibition",
      "stage": "Preclinical",
      "mechanism": "CaMKII inhibitor",
      "focus": "Arrhythmias with potential AF applications",
      "company": "Vasa (reported by BioWorld)",
      "latest_update": "Preclinical results reported for blocker-resistant arrhythmias",
      "tags": [
        "CaMKII",
        "preclinical",
        "arrhythmia"
      ],
      "trials": [],
      "notes": "Preclinical CaMKII inhibitor reported for blocker-resistant arrhythmias; AF applicability not yet established.",
      "sources": [
        "https://www.bioworld.com/articles/691533-preclinical-results-show-potential-of-as-100283-a-camkii-inhibitor-for-the-treatment-of-blocker-resistant-arrhythmias"
      ]
    },
    {
      "id": "maxwell-srt",
      "name": "Spatial Resynchronization Therapy (SRT)",
      "type": "Device",
      "category": "Neuromodulation - Cardiac Pacing",
      "stage": "First-in-human completed; clinical study expanding",
      "mechanism": "Multi-site low-energy atrial pacing with Rhythm360 algorithm",
      "focus": "AF rhythm control and atrial function restoration",
      "company": "MaxWell Biomedical",
      "latest_update": "ClinicalTrials.gov update posted 2022-07-18",
      "tags": [
        "neuromodulation",
        "pacing",
        "AF-HFpEF"
      ],
      "trials": [
        {
          "name": "SR-TheAF / SRT first-in-human",
          "phase": "First-in-human",
          "status": "UNKNOWN",
          "readout": "Proof-of-concept termination of AF",
          "readout_date": "2023-06",
          "registry_id": "NCT05461612",
          "note": "Initial experience with SRT in AF patients"
        }
      ],
      "notes": "Implantable system delivering imperceptible, adaptive multi-site atrial pacing; non-destructive alternative to ablation.",
      "sources": [
        "https://www.maxwellbiomedical.com/news",
        "https://www.maxwellbiomedical.com/"
      ]
    },
    {
      "id": "maxwell-mpt",
      "name": "MultiPulse Therapy (MPT)",
      "type": "Device",
      "category": "Neuromodulation - Low-Energy Defibrillation",
      "stage": "Clinical experience (legacy studies)",
      "mechanism": "Ultra-low-energy defibrillation/cardioversion pulses",
      "focus": "AF and VT cardioversion",
      "company": "MaxWell Biomedical (Cardialen assets)",
      "latest_update": "MaxWell acquired Cardialen\u2019s assets; MPT described as low-energy cardioversion therapy",
      "tags": [
        "neuromodulation",
        "cardioversion",
        "low-energy"
      ],
      "trials": [],
      "notes": "Cardialen\u2019s MPT technology acquired by MaxWell; designed to restore rhythm using timed ultra-low-energy pulses.",
      "sources": [
        "https://www.maxwellbiomedical.com/cardialen-acquision",
        "https://www.prnewswire.com/news-releases/maxwell-biomedical-completes-acquisition-of-cardialens-assets-301702748.html"
      ]
    }
  ],
  "weekly_updates": {
    "conference_abstracts": [
      {
        "title": "Volt PFA 12\u2011month data \u2014 AF Symposium 2026",
        "date": "2026-02-06",
        "source": "Abbott"
      },
      {
        "title": "Field PULSE FIH data \u2014 AF Symposium 2026",
        "date": "2026-02-05",
        "source": "Field Medical"
      },
      {
        "title": "CellFX nsPFA 360 FIH data \u2014 AF Symposium 2026",
        "date": "2026-02-05",
        "source": "Pulse Biosciences"
      }
    ],
    "guideline_updates": [
      {
        "title": "2023 ACC/AHA/ACCP/HRS AF guideline (current US standard)",
        "date": "2023-11-30",
        "source": "ACC"
      }
    ],
    "safety_signals": [
      {
        "title": "Andexxa (andexanet alfa) \u2014 FDA safety communication on thrombotic risk",
        "date": "2025-12-18",
        "source": "FDA"
      }
    ],
    "label_expansions": [
      {
        "title": "FARAPULSE PFA \u2014 expanded labeling for persistent AF",
        "date": "2025-07-07",
        "source": "Boston Scientific"
      }
    ]
  }
}